Go back

#416 ‒ The science of mitochondria: their role in health, aging, and disease, and what the evidence says about drugs and supplements aimed at improving their function | Navdeep Chandel, Ph.D.

2h 6m 31s

#416 ‒ The science of mitochondria: their role in health, aging, and disease, and what the evidence says about drugs and supplements aimed at improving their function | Navdeep Chandel, Ph.D.

Mitochondria are far more complex than the "powerhouse of the cell" label implies. Nav Chandell emphasizes that their primary functions extend beyond ATP production to include signaling through reactive oxygen species (H₂O₂), regulation of immune responses via mitochondrial DNA/RNA release, and control of epigenetic processes through metabolites like alpha-ketoglutarate. These signaling roles are crucial for cellular adaptation, immune function, and gene regulation. Contrary to popular belief, H₂O₂ is not inherently toxic but serves as a key regulator of cellular activity; excessive antioxidant supplementation fails because healthy individuals already maintain sufficient endogenous defenses. The idea of "mitochondrial dysfunction" as a core driver of aging is challenged by evidence showing that mitochondrial mutations—whether in nuclear or mitochondrial DNA—do not rapidly induce aging phenotypes in animals, suggesting it is not a necessary component of aging. Instead, subtle disruptions in signaling and metabolite levels may play a more significant role. Metformin, a widely used drug, shows complex effects on mitochondrial biology, with evidence for both benefits and limitations, though its anti-aging potential remains inconclusive due to inconsistent clinical trial results. Practical assessment of mitochondrial health can be achieved through exercise-based tests like VO₂ max and lactate threshold, which reflect aerobic efficiency. Ultimately, the conversation shifts from simplistic views of mitochondrial failure to a nuanced understanding of metabolic signaling, cellular communication, and individual variability in aging.

Transcription

22982 Words, 130133 Characters

English
Hey, everyone. Welcome to The Drive Podcast. I'm your host, Peter Attia. This podcast, my website, and my weekly newsletter all focus on the goal of translating the science of longevity into something accessible for everyone. Our goal is to provide the best content in health and wellness, and we've established a great team of analysts to make this happen. It is extremely important to me to provide all of this content without relying on paid ads. To do this, our work is made entirely possible by our members, and in return, we offer exclusive member-only content and benefits above and beyond what is available for free. If you want to take your knowledge of this space to the next level, it's our goal to ensure members get back much more than the price of a subscription. If you want to learn more about the benefits of this content, please visit www.thedrivepodcast.com. If you'd like to receive a free copy of our premium membership, head over to peterattiamd.com forward slash subscribe. My guest this week is Nav Chandell, returning for his second conversation on The Drive. I believe Nav was on in late 2018 or early 2019. Nav is a distinguished professor of medicine, biochemistry, and molecular genetics at Northwestern University, where he studies mitochondrial biology and the role mitochondria play in aging and chronic disease. He's one of the most thoughtful scientists in the world, and he's also a professor of medicine and I know in this space, especially when it comes to separating what we think we know about mitochondria from what the data actually support. And of course, everybody knows that mitochondria is almost a laughable buzzword at this point in health circles. So I thought it would be really important to have on the world's expert on this topic so that we could separate signal from noise. In this episode, we discuss what mitochondria actually do beyond ATP production, which I think is what everybody understands. Why their real job is often misunderstood, how mitochondria regulate signaling through reactive oxygen species, and why that matters for immune function, the role of mitochondrial metabolites in epigenetics, gene regulation, and cellular adaptation, how mitochondrial DNA can trigger inflammation, and how that intersects with aging, what quote mitochondrial dysfunction really means, and why it's often used too loosely in aging conversations, why metformin remains one of the most interesting drugs from mitochondrial biology despite decades of use, and why it's often used too loosely in aging conversations. How metformin actually behaves in the body, including its distribution, tissue-level effects, and gut-centric mechanisms, the relationship between mitochondria inflammation and environmental stressors like pollution, a practical rundown of popular mitochondrial supplements, and what NAV thinks the evidence does and doesn't support for each of them, where compounds like urolithin A and alpha-ketoglutarate fit in under this broader mitochondrial conversation, the mechanistic appeal, and real-world limits of what mitochondria are capable of. Let's get started. How metformin actually behaves in the body, including its distribution, tissue-level effects, and gut-centric mechanisms, the relationship between mitochondria inflammation and environmental stressors like pollution, a practical rundown of popular mitochondrial supplements, and what NAV thinks the evidence does and doesn't support for each of them, where compounds like urolithin A and alpha-ketoglutarate fit in under this limitations of interventions like methylene blue and hyperbaric oxygen. Going into this podcast, I thought I understood most of what the mitochondria did, and I have to say I came out of this scribbling down many notes realizing that my own understanding of this space expanded significantly, and so for that reason, I'm pretty confident everybody listening to this is going to share my enthusiasm for this topic. So without further delay, please enjoy my conversation with Nav Chandell. Nav, good to see you again, my friend. Great to see you. Thanks for the invite. Thank you for coming down. I suspect that a number of people listening to us today may have not heard us speak eight, six, seven years ago. I don't remember. If they did, I'm sure it's easy to forget, and there's so much new stuff to talk about. But I always like to kind of ground people in what the mitochondria are. Unfortunately, mitochondria has become one of the top 10 buzzwords on social media. So I'm going to talk about what the mitochondria are, and I'm going to talk about what the mitochondria are, and I'm going to talk about what the mitochondria are, and I'm going to talk about what the mitochondria are. So there's no chance that anybody listening or watching us hasn't heard the term, but that second and third order understanding might be a little foggy. And given that we're going to talk so much about mitochondrial health, which is a big buzzword, mitochondrial boosters, and all these other things, we do need to ground this discussion in what mitochondria are. So take it away. Yeah, thanks again, Peter. I agree with you. I think it's not only mitochondria, but the other big buzzword is mitochondrial dysfunction. That's the real buzzword, which you hear over and over. So if you're going to talk about mitochondrial dysfunction, you're absolutely right. Why don't we start with mitochondrial function? Now, mitochondria do a lot of things, and I'm sure my colleagues will be like, Nav, you didn't discuss X, Y, and Z. So we're not going to discuss how mitochondria are made or degraded and how many different kinds of mitochondria there may be. There's a lot we can cover. We're going to focus on one thing, mitochondrial function. What do mitochondria functionally do? Most people don't know how to do it. They don't know how to do it. Most people know it as the powerhouse of the cell because it makes the ATP. And that gives you the power for your muscles, your neurons to fire. And for a long time, most of us just thought about mitochondria as an ATP generator. So when mitochondrial dysfunction comes, does it happen in aging or in heart failure? It's, you don't make enough ATP. Now remember, glycolysis can also make ATP, but mitochondria is much more efficient and can give you a lot more. So very simple. And all the great theories around mitochondrial dysfunction related to any particular disease, if it is causal, or the natural aging process is all about ATP. Well, I'm here to tell you, we're not going to talk about the ATP because there's a lot more they do. So just to back up, the electron transport chain generates a protomotive force, basically a voltage, which can be harnessed to make ATP. That process is coupled to something called the Krebs cycle, or the TCA cycle. And it turns out that the TCA cycle is the anabolic engine also in your cells. So mitochondria do two things. They make ATP, and they can make the building blocks, the metabolizer of the building blocks for new lipids, new nucleotides like DNA, RNA, amino acids for the building blocks of the protein. And that's a law. People forgot that mitochondria is an anabolic engine. We'll get into it with cancer in a second. So that's what, classically, the great biochemist of the 20th century taught us. And that's, like I said, it's in your textbooks. What has changed in the last 30 years, and I think I've been part of that revolution, is that mitochondria also communicate. They're just not an organelle sitting on the side. And things like mTOR, when they get activated or deactivated, mTOR is a big decision maker of metabolism. Your genes being turned on and off, they're deciding cell fate, how a cell is, what it does. And mitochondria is just sitting there giving you ATP, giving you metabolites. It has no decision-making properties. Well, that's changed. Can we back up for one sec now and just give folks maybe a sense of size and scale? So are there any cells in the body that don't have mitochondria in them? Red blood cells. Okay. Absent red blood cells, when you consider all the other cells which have mitochondria, what is the approximate cellular density of mitochondria? It depends. Yeah. So let's talk about a neuron. A neuron might have approximately how many? Actually, I don't know these numbers, to be honest with you. The hepatocytes are full of them. We're talking thousands. Yeah. For sure. Maybe more. Maybe more. But again, instead of worrying about are they dense or they're not dense, I think if you look at them from what they're doing, there's the ATP, there's the metabolites. But what I really want to get into is the third aspect, which a few mitochondria could probably fulfill. And so that way, you don't have to always think about mitochondrial biogenesis. I think that's why you're asking this question. We're thinking of it in terms of supply and demand mismatch, for example. So are they being paired to cells in density based on energy need or metabolite need? Because, for example, a hepatocyte doesn't actually need much ATP, but it needs a lot of anabolic precursor. It makes glucose, for example. I assume that in the hepatocyte, the density is optimized more towards anabolism, whereas in a very energy-dense cell, like a muscle cell, where ATP is probably more important than precursor to building blocks, you're optimizing around this other function of ATP generation. That's basically where I was asking. On a first approximation, that's true. Although, because there's a third function, that simple theory, I don't disagree with that. I just don't think about it anymore in those simple terms, because there's a third function that is becoming very dominant. And I actually don't know this third function I'm going to talk about. But I'm going to talk about it in a little bit. I'm going to talk about how it fits into that paradigm that you just explained. And that's why I've stopped thinking about more or less mitochondria. And that third function is that mitochondria are constantly generating signals to the rest of the cell. These signals are optimized for cellular function. What are these signals? One of them is the electron transport chain is not a perfect system, and it leaks electrons. It can leak a little bit of electrons or a lot of electrons, to make H2O2, make superoxide first, and then H2O2. People used to think H2O2, hydrogen peroxide in cells, damaging, damaging, damaging. In fact, the oldest theory of aging says that as you get older, your mitochondria degenerate, and they make copious amounts of H2O2 to cause degeneration of the muscle, of the neuron. I do want to just make sure people understand how that's happening and why it's happening. I think a little bit of biochemistry won't kill someone. So, When Acetyl-CoA is running through these four structures these four complexes across the electron transport chain. It's not that. Acetyl-CoA is part of the Krebs cycle. Yeah, we can get into it. Yeah, we can do a little biochemistry. It's okay. So you go from glucose to pyruvate. Pyruvate comes in the mitochondria. Pyruvate becomes acetyl-CoA along with oxaloacetate to jumpstart the TCA cycle. Let's just look at that first step. The pyruvate to acetyl-CoA, it takes an NAD molecule and makes NADH. NADH is full of electrons. It goes to complex I of the electron transport chain. Complex I takes that NADH to electrons and makes NAD. The reason why people are so interested in NAD precursors is they're thinking their complex I is not working so well because it's not giving back the NAD to make mitochondria run, to generate ATP in the TCA cycle. So if I give a lot of NAD, maybe I can overcome that. The complex I deficit, which is found in Parkinson's linked and whether it's linked to normal aging is debatable and we'll get into that. And so that NADH electrons now are going to go down the electron transport chain with the final acceptor of those electrons being oxygen. The best analogy I can think of is a waterfall through a tube and it's going through a tube into a tank. The tank is the oxygen that's accepting all that water. There are holes, very tiny little holes in that tube. That's that leak. And that leak can increase or decrease depending on how full that tank is. If the tank is completely full, all of that water backs up and now you get that leak happening because it has to go somewhere. So that's a simple way to think about it. The best analogy I can think of is you have this NADH, which has these two electrons and it passes it down the electron transport chain, keep it simple, and oxygen is the final acceptor of it. This allows the NADH, when it passes those two electrons, it regenerates NAD and it keeps the TCA cycle going. But that electron transport chain isn't perfect. Not every electron always gets to oxygen. There's a little bit of imperfection, a little bit of leak, and that one electron can take oxygen to something called superoxide, which becomes quickly converted by some enzymes called superoxide dismutase to make H2O2. So what people thought is, well, the electron transport chain, this slightly imperfect system, becomes more imperfect. So now it's leaking more electrons in neurodegeneration and cancer and everything, and now it's making copious amounts of H2O2. And is there evidence, by the way, Nav, that even in an absent disease state, as a person ages, as they go from 10 to 20 to 30 to 40 to 50 to 60, what we represent in the textbook, which is the final output after you've transferred all the electrons, is that you've made all of the electrons and made all of the ATP, you have two outputs: carbon dioxide and water, which is what we are all breathing out. Coupled to generating ATP. Yep. Is the idea that absent disease, just aging, increases the fraction of H2O2 relative to just H2O? I don't think so. Okay. Interesting. I wanted to go through this just so people understand what H2O2 is relative to the normal process of H2O. Right. So what you're asking me is, in a normal person, does the system become leaky? Just by age. Just by age. I don't think so. This is one of the new paradigms. It's not written in stone yet, but this is what we've been working on. Not only that, but let's back off. To begin with, do we make copious amounts of H2O2 to levels that become toxic? I don't think so. We have a lot of antioxidants, Peter, that keep that in check. Explain to folks what an antioxidant is. We're talking about H2O2, which is a protein that can detoxify different molecules of reactive oxygen species. So there's a family of proteins called superoxide dismutases. They take superoxide and make H2O2. H2O2, when you make it, has three choices. First choice, which almost happens, is because we're full of proteins that degrade it to water. So there's two classes. One is catalase. The other one is peroxyredoxins. They really have high reactivity to it, and they convert it to H2O. I don't want people to lose the thread. H2O is a very stable molecule. Very stable. Okay. So you have oxygen. It has these covalent bonds to hydrogen. Very stable. You have a couple electrons that can create polarity. But why is it not reactive in a way that H2O2 is reactive? Actually, H2O2 is not that reactive. Superoxide is super reactive. But there are cysteines, which can readily get oxidized. That is by H2O2. And that's part of the second thing that I was going to talk about, which is this cysteine on certain proteins. And we don't quite know the code of that still. That changes is the activity of that protein, and that's all signaling. That H2O2 with iron can undergo a Fenton reaction to make hydroxyl radical. It doesn't last long, and it's super toxic. It will react with anything that it touches. That can. Even with a polyunsaturated fatty acid can make something called lipid peroxide and start a chain reaction, which is now called ferroptosis. It's a new form of cell death discovered about 12 years ago. So the more we create H2O2, the more we theoretically risk this process. The ferroptosis process. Yes, exactly. So you make the H2O2, lots of proteins to get rid of it. You always need a little bit, we think, for that signaling. That's the thing. That's cysteine oxidation. But if you overwhelm these antioxidants, for whatever reason, for some reason the antioxidant capacity goes down, you start to push that not only for the signaling, but you start to push it towards this ferroptosis. And when people hear antioxidant, they automatically, I would assume, think of things that we eat that are known to have antioxidant properties, such as vitamin A or vitamin E or vitamin C. C, yes. Yeah. So how much of an individual's antioxidant buffer capacity is. Vitamin C is a function of how much antioxidant they consume, or is that an overly simplistic way to think of it? No, no, no. So the toxic ones that I'm talking about, the lipid peroxide, so vitamin E is pretty good at that, at detoxifying that, okay? Probably the biggest one is selenium. So the proteins that are responsible in our bodies to get rid of those lipid peroxides, it's a battle, right? You're making these hydrogen peroxide, you're making lipid peroxides, but we, most of us, have enough. We have enough of, for lack of a better word, antioxidant capacity, Peter, to keep those levels in check. So selenium. There are countries, by the way, which are a little bit selenium deficient. Northern New Zealand, Sweden, Finland, the US has a high selenium diet. And that's based on the soil? The soil. So just to finish, selenium is required for the proper activity of proteins like GPX4, which get rid of those lipid peroxides. Because it accepts electrons easily or.? Selenium is part of the GPX4. Ammoity. Ammoity to make it work. But this is my point. If you have a proper diet, you should have enough antioxidant capacity. There are places that may be deficient on it. I just want to make one thing about vitamin C, the granddaddy of them all, as they say. Vitamin C, and we're going to talk about, going back to my signaling, is a very important protein, not for its antioxidants, but as a co-factor for a whole class of enzymes called the alpha ketoglutarate dioxygenases. All the epigenetic clock stuff that people like, this is run by these enzymes, and vitamin C is needed to make sure those enzymes run. Two oranges a day is enough to make those enzymes run. And so is it your point of view that all of the trials that have looked at supplementing with antioxidants, they've all failed? Yes. Proven no health benefits? Some cases worse with cancer? Yes. Is your hypothesis for why that's the case that, A, we have sufficient antioxidants, and B, we don't need them anymore? We have sufficient enough antioxidants in the diet, so giving more doesn't really do anything. Is it, B, that we're not taking enough, so the antioxidant trials failed because they failed to give enough, and you would have to give really, really, really high doses to get the benefit? Or, C, actually they do work, but they're taking away the reactive oxygen species, which we need to do something valuable, or D, something else? A and C. In other words, most of us have enough. I agree some countries may have low selenium, so they may want to take selenium in them. There are people who don't eat enough oranges or have enough — they're not scurvy — but, you know, there's actually quite a large level of differences in vitamin C levels in people. But generally, if you're eating a healthy diet, I think it's the A. The other part is that people who are taking gobs of it might be interfering with the normal functions. Remember, I said something like H2O2 can become damaging if it becomes lipid peroxide. Something like vitamin E can take care of that. But there's also this need to keep this cysteine oxidation, what I call signaling. And my lab has really worked a lot on it. And we've done genetic experiments where we decrease mitochondria's ability to make H2O2, for example. A T cell, when it sees a pathogen, will proliferate okay, but it won't make the memory T cells. So it actually hurts the T cell. It hurts the T — well — Hurts the immune cell. Hurts the immune system. Hurts the immune cells, yeah, for functioning properly. And there are some data, like in sepsis trials, which have failed — in fact, made it worse. There's the antioxidant trials in those cases. So I think we have enough, and sometimes, it might interfere with normal biology. And I think this is a paradigm shift. It used to be anti — oh, sorry, oxidants, bad, bad, bad. Take antioxidants. It's a little bit a little nuanced. H2O2, good, within levels. If it becomes lipid peroxides, they can be managed due to these selenium-dependent enzymes. Bingo. That causes DNA damage and everything. All right. So let's go from function to dysfunction. Can we just go back to function? Because I only talked about one of the H2O2. Oh, sure, sure. There's a lot of them. Let me just give you two more, which are important for this discussion. The second one is metabolites. So those TCA cycle metabolites that are linked to electron transport chain, including acetyl-CoA, you just mentioned. Alpha-ketoglutarate. Alpha-ketoglutarate. So it turns out that protein acetylation, when proteins get acetylated at lysines, is a way to change their function. A lot of the acetyl-CoA comes from mitochondria. So you could see how mitochondria controlling acetyl-CoA levels. Probably one of the three most important things that drives autophagy is acetylation of protein. Yeah. Well, the big one is also in the histones being acetylated to keep a chromatin open or closed. That, mitochondria control. So that's a signaling aspect of mitochondria now. It has nothing to do with ATP. Alpha-ketoglutarate. So there's 75 enzymes called the alpha-ketoglutarate dioxygenases. They use oxygen and alpha-ketoglutarate. They use iron, Fe2+, and they make succinate. To recycle that iron, you need vitamin C to make them functional. So when you don't have enough vitamin C, those enzymes aren't working. So let's just go through those. So now, again, you have alpha-ketoglutarate as an input from mitochondria into running 75, I would argue, some of the most important enzymes. The enzymes that cause DNA methylation to be DNA demethylation or alpha-ketoglutarate. Histone demethylases. The collagen-prolyl hydroxylases, you and I hopefully have good skin as we age, which are alpha-ketoglutarate dioxygen. In fact, the vitamin C that people like to put on their skin, I always argue, is because you keep the collagen-prolyl hydroxylases from working properly. So now you have, think about it, your DNA demethylation. If your DNA is hypermethylated, you typically turn off genes. The epigenetic clock phenomenon, and I think you've discussed a lot about whether it's of any value or, you know, and I'm not going to debate that, but all I'm going to say is that people who are so into their epigenetic clocks, alpha-ketoglutarate, alpha-ketoglutarate is controlling those clocks because they're needed to keep the demethylase reactions going properly. So that's our second major, major function. Right. So you have H2O2, you have TCA cycle metabolites controlling essentially epigenetics. Your third one is, so mitochondria has its own DNA and RNA. If it spills out, the same sensors that look at pathogens, we have things that say, I'm infected with a pathogen. I have to turn on a cytokine. Well, the mitochondria, your bacteria, the current theory of how we have a normal eukaryote is an archaea, which is not a bacteria, it's a kingdom by itself, and an alpha proteobacteria. The two of them had a symbiosis before oxygen was around. So there's a bacteria within us. And if that bacteria releases its DNA or its RNA, it's viewed as a foreign in the same inflammation pathways. And sorry, why is it that we didn't thymically, why were we not exposed to that? Basically, why did our thymus not account for that? Because there must have been some disruption of mitochondria during embryogenesis. Great question. Actually, I don't know the answer to that. One thing could be that some of those antigens are not presented. They're not as easily presented because they're hidden and because they're in the mitochondrial matrix. But the key point, just to sort of wrap this up, I mean, there's many other things that mitochondria release, okay? And again, to the listeners, especially my colleagues, it's just in the interest of time for our discussions. We're going to keep at least three of them. There's many more. One is H2O2 needed for immune function as we've needed for cell differentiation. Alpha-ketoglutarate, which we want to talk about later in the supplement section, and keeping the epigenetics going in a proper way. And lastly, sometimes mitochondrial DNA or RNA being released is to turn on immune function. And again, like with immune function, if it's chronically, you know, some people think it's not your ATP, Peter, you asked whether it's decreasing with age or H2O2 increasing. Could it be we just have leaky DNA from mitochondria? Why is that a good thing, Nav? Because. No, no, no. I'm not saying chronically leaking is not a good thing. No, no. But I'm saying you mentioned earlier that if the mitochondria releases its DNA and or RNA, it's going to activate the immune system because it's not identified as self. But that activation of the immune system is very specific. So what is it targeting besides the DNA and RNA of the mito? So there's two big questions in that field. How it gets released, it's not known. It's not mitophagy or. People argue that improper mitophagy might release it or the normal turnover, fission-fusion. Where H2O2, we know how it's released. Alpha-ketoglutarate has actual transporters. This one is a bit of a black box. But once it's released, we know the target. C-gas sting, thing, MAVs for the RNA. So there's dedicated. And what do those T-cells go and do? Who do they turn their ire on once they're activated? Right. Not only T-cells, but any cell can release it. And the signals they release are type 1 interferons, which can then orchestrate the whole immune system. But I think the question you're asking is, is this a regulated system? And is it for a net positive? In other words, is this something we are doing to amplify an immune response? So if a virus comes in you, if influenza comes along and attacks the endothelium or the epithelium. Epithelium, rather, of your throat, is it also something that the mitochondria do? Say, how can I participate and help the organism? I'm going to release RNA and DNA. It's going to make more interferon. It's going to make more T-cells, more B-cells. Is that the theory? Absolutely. In fact, people have done those studies. They've taken different viruses. I did one, helped a colleague in Northwestern, where they did pox viruses. Good old pox viruses. And lo and behold, mitochondrial DNA gets released. They used to turn on exactly what you're saying. What's the signal? How does it know to do that? Yeah, exactly. So the mitochondrial DNA, if I had to compare H2O2 versus the DNA, H2O2 is still a black box what it hits. Which proteins, which cysteines, we know how to manipulate. Mitochondrial DNA, we know the receptors it's going to hit. I don't think, people might argue, I don't think we have a good explanation how it gets out. And if we knew there was a select transporter or something, then we can manipulate it, maybe even make drugs against it, depending on what you want to do. But what I was going to get at is mitochondria with two membranes. I could imagine, Peter, a scenario where you're making enough H2O2, you're making enough ATP, you're making enough TCA cycle metabolites like alpha keto glutarate. So everything is great. But you know what's not great? Is maybe the membranes are not perfect, and they're leaking a little bit of mitochondrial RNA or DNA. And by releasing a little bit of mitochondrial RNA or DNA over 20, 30 years, it's going to be a little bit more of an immune response. A little low-grade inflammation all the time. So some people think maybe the autoimmunity that you get as you age, or the inflammation aging might be of leaky mitochondria. Not enough that it compromises DNA, not that it compromises alpha keto glutarate, or even my beloved H2O2 signaling, but it just sort of leaks out at low levels. And that's the increase in inflammation that we're seeing. It's a hypothesis. It's difficult to test because exactly what you pointed out, how does it get out? Because if I knew how it got out, I could then come in and stop it in a mouse model or whatever and say, look, here's the aging, inflammation aging, and now it's not happening. Do you know, Nav, that it gets out of a cell that remains? Or does getting out imply that that particular mitochondria, that organelle was destructed and it's binary? Anytime DNA and RNA get out, it means that particular organelle is gone versus this idea of a leaky organelle. You hit it on the thing. We don't know that. Well, this is my problem with the idea. I've always assumed, you know what, we forgot to, actually, this is a perfect segue. I forgot to mention the most important experiment done in signaling by Zhao Dongwang, which got people like me inspired in the mid-90s to think of H2O2 and other things, which was that he showed that cytochrome C, which is part of the electron transport chain, part of electrons flowing, making ATP, if it gets out from the mitochondria, that cell goes on to die. The mammalian death signal is cytochrome C getting released. Now, there's something called where cytochrome C can get a little released and the mitochondria can repair itself. Many people think the mitochondrial DNA must be doing that. So, in other words, it's not during cell death. When I first saw it, I was like, the cell's about to die. It's just turning on inflammation. Exactly on first principles. But it looks like there's improper, maybe permeabilization or some leaky mechanism I don't understand. And I actually struggle with it, that how does it really work? Because to me, it would seem binary, but people argue now that cytochrome C even, which is binary, that there is cytochrome C a little bit gets released and then it can repair itself and it's turning on stress signaling. So, more to be discovered on that front. So, let's put a bow on this because the two biggest and most obvious things that the mitochondria does, which is generate ATP, anything that interrupts that significantly is incompatible with organism life. That's not true. I mean, cyanide. If you interrupt that process, we're done. If you stop making ATP, you're dead, right? That's what I mean. So the cyanide one is an interesting one because if you do these experiments genetically, so cyanide binds to cytochrome oxidase and sort of carbon monoxide and many other things. But if we genetically in a heart or in a dopaminergic neuron or even in a muscle, three bioenergetically heavy things, there are signaling pathways such as activation of AMPK, which can turn down mTOR. That cell lives fine for months and months and months. It's on glycolysis. So you're saying it's not that it evolves away around that particular complex within the mitochondria. That's very interesting. Why is it? And by the way, here's a crazy thing. Colleague of mine at Northwestern knocked out components of the electron transport chain. The heart continued to pump on glycolysis. For how long? Once. And then, but you know what happened? All this signaling that I'm talking about, and he doesn't understand all of it, but that signaling caused it to hypertrophy. And now it can't contract and the mouse dies. But why is it then that cyanide is so lethal in seconds? Why can't the organism survive on glycolysis for a while? I think because when we genetically do it, and by the way, I actually don't know why, which organ failed. So the ones that we've done, we don't actually know. Same with rotenone, which is a complex one inhibitor linked to Parkinson's. So if we do the same experiment in dopaminergic neurons, those neurons basically live off glycolysis for three months in a mouse, and then the neurons start to die. But during those three months, they stop making dopamine. So in other words, they have enough energy to live, but not to be functional. All right. I'll take my extreme statement back. So it's not about death. It's profound dysfunction. But it's dysfunction. But the question is, why is that dysfunctional? Yeah. But clearly, top hierarchy function of mitochondria make ATMs. Another big function of mitochondria is make metabolic building blocks. And then the third one I'm calling 3A, 3B, 3C, and those are the three things you just talked about. So that's the H2O2. That's the protein acetylation and histone acetylation, all of the acetylation pathways. And then the third one, which is, I mean, three, call it 3C, the really radical sounding one is actually it's to release genetic material to heighten immune response. Right, right. Also, the fourth one you could argue is cell death, cytochrome C release. When it gets released, that cell typically goes on to die. Oh, it's the whole cell, not just that mitochondria. Oh, no, no, no. Cytochrome C turns on caspases. It's the apoptosis signal. Apoptosis signal. Yeah. The mammalian apoptosis, the dominant mammalian apoptosis signal is when the cell gets neglected for whatever reason, it releases cytochrome C, and that cell goes on to die. Yeah. So mitochondrial cell death clearly is a big thing. And there's many others. There's many others as well. Your favorite mTOR, when mitochondria, I think the reason in our experiments they can survive the organism or the organelle, I mean, sorry, the cell can survive for long periods of time, even though it's not functional because it's not making the signals or metabolites, is that AMPK gets activated when mitochondria don't make enough ATP. And AMPK will tell mTOR to shut down the anabolic processes. So it's just saying, let's hold on to the cell, live off glycolysis. Yeah, we can't make, you know, take all the building blocks or dopamine for dopaminergic neuron. But then there's some cells like the heart that still starts to grow. It's crazy. We don't quite understand all of this. But this is a new way to think about, I mean, for the listeners, I want them to not only think about ATP as the hierarchy, not only the metabolites, but all of these interesting communication of signaling. The nice thing about all these signals is if we know how these signals are being released, maybe we can modify them in particular diseases. Yeah. And if there's a person listening to us or watching us who wants to know how well their mitochondria function, what test can they do? I have my favorite, but I want to know yours. Okay. I have none. You have none? I have none without taking a biopsy. All right. Well, tell me if you do a biopsy, what you're going to do? What are you going to look at? Where are you going to biopsy? The muscle? Exactly. Okay. I don't know. What assay can you do in the lab? You can do metabolomics. That'll tell you your TCA cycle metabolites are up or down in a snapshot. It's not perfect. It's not perfect. You can take those and do isolated mitochondria and you can look at maximal efficiency. I don't know how useful that is because here's the reason. What human genetics has taught us from mitochondrial mutations, the people who have genetic mutations either in their DNA, their nuclear DNA or their mitochondrial DNA, which causes their proteins to be dysfunctional in their mitochondria, you have to lose 70% of mitochondrial protein function. It's that redundant. It is that much redundant. It's that much excess capacity. Makes sense. I mean, if you're going to have something that is that critical to life. Right? So you and I start, let's say at 100% and you can go all the way down to 70% and 80% in almost every tissue before- 20 to 30, you mean? Yeah, yeah. Yeah, yeah, yeah. But 20 to 30, sorry, left- Yeah, remaining. That are remaining. So here's the analogy. You're a car guy, remember? So we're going to use the good old Aston Martin because I like James Bond. The last one in No Time to Die, I think in the last movie, that Aston Martin, I looked it up yesterday, 217 miles an hour. My favorite one, the classic 1964 James Bond and the Goldfinger one goes about 140 miles an hour. Now you could look at those two and say, "I don't want this one, man. This one's not." In the city of Chicago, you can only drive 50. It's just not rate limiting. That's the best way to think of it. So when you're measuring it, how do you figure out it's rate limiting? Okay. Well, let me extend your car analogy then, because I love that analogy. You're looking at one parameter of the car, which is speed. Is speed, in your analogy, production? It is just the ability to maximally consume oxygen. That's the first one, by the way. Yeah, yeah. So my question to build on your analogy is the newer Aston Martin doesn't only go faster, it's more fuel efficient. It has better suspension. It handles better. The transmission is infinitely better and smoother, et cetera, et cetera. Can you infer from function one, remember, I'm going to talk about these now, is function one, two, three A, three B, three C, et cetera. Can you infer from function one, the capacity of two and three? You can, number two, because what you can do in an isolated mitochondria is you can just feed it all sorts of carbons, fatty acids, pyruvate, whatever you want, and ask how fast it can run at top speed. But then you can also give it ADP and ask it how well it can make ADP. That's that fuel efficiency. So we can definitely do those two things. And there are people, and then also you can measure its ability to generate H2O2. But we have no idea what that tells us about its ability to control the immune system or these other much more nuanced ideas. Right, right. And then there are parameters like their metabolite lactate pyruvate ratio, beta-hydroxybutyrate acetoate. That's an NADH, NAD surrogate that people use in patients with mitochondrial mutations. Those levels, they have to be quite high. When a normal person you're not going to, I mean, then there's something wrong. There's medically something wrong. So you're talking about something as a canary in the coal mine kind of thing. So here is my test. Here is my favorite way to determine mitochondrial function. And it's purely focused on the first one. It is oxygen and ATP. You put a person on a bike or a treadmill or something like that, and you see how much work they can do in watts or mets while keeping lactate below two millimole. Because as long as lactate is below two millimole, in steady state, this person is maximizing mitochondrial capacity. Once lactate starts to rise, you know that they have hit that threshold and now they are shunting through glycolysis. So the difference between me and Tadej Pogacar, who's the greatest cyclist in the world, it was actually just an article that came out in a medical journal very recently that looked at the fact that his VO2 max, they predict, is the highest of any professional cyclist ever. And his ability, he can maintain seven watts of output per kilogram longer than any cyclist they believe has ever been able to do so. So if you put me and Pogacar on a side-to-side ergometer and we tested this, once I hit about 230 watts, my lactate is going to start going up. I can't keep it below two. Pogacar is going to get to 350 watts. And if you normalize that for body weight, it's even more profound. He, therefore, has much healthier mitochondria than me. Would you agree? More efficient? Well, again, I haven't thought about sports medicine as much as you have, so I'm going to ask you the question back. My understanding is that it's not only the mitochondria efficiency, but the delivery of oxygen by the vascular, that's the other determinant. A hundred percent. But at that point, neither of us are rate limited by oxygen delivery. How do you know that? I know that because we're only at about. 60 to 70% of VO2 max when we're at that state. So in other words, we're still well inside the envelope of what the cardiac output is determining. By the time cardiac output is limiting you, you are generally in a glycolytic state. Okay. So just to be also for the listeners and for my own, there is the heart, there is the blood flow. So those are two inputs in the system. And the third one is how efficient mitochondria is using that oxygen to make ATP, to keep you going so you don't use your phosphocreatine, and glycolysis, so lactate goes up. Those are the three inputs. And you're saying that you're measuring this at a time when you're at least confident that you're not you and this great cyclist. And anyone, truthfully. Oh, anyone, let's say, is not limited, rate limited by the contraction as well as the delivery, and is simply the mitochondria. Can I buy that? We do this test on all of our patients. I've never seen a case where a person's what's called LT1, lactate threshold one, which is about this zone two, is not in the vicinity of 60% to 70% of ventilation max. Now, there are other components going on, and I want to be thoughtful about it. We're not going to go down the rabbit hole too much on this. But of course, the amount of type one muscle fiber a person has is going to play a role. There are other factors. But I guess my point, Nav, is this strikes me as a really good poor man's test for mitochondrial function. You can't do this without healthy mitochondria, and you can't do what Pogacar does without very healthy mitochondria. But let's go. Let's go back to my Bond analogy. As I age, do I need to have fuel efficiency, all of that, even like the James Bond 1964 car? Probably not. It depends on how much physiologic reserve you want to have. Because at some point, I mean, using VO2 max as an analogy, let's assume I measured your VO2 max today, and it was 42. I don't have a nomogram in front of me, but I would put you in the top quartile for your age. That number is going down at about 10% per decade. Yeah, yeah, yeah. Now, there is a point. There is a point beneath which, meaning there is a VO2 max point that once you go below that, it impacts daily living. Now, that depends on what you define daily living as. For Peter Attia, that number is about 28 to 30. Once my VO2 max falls below 28 to 30 milliliters per kilogram per day, my quality of life will suffer dramatically. For some people, that number is 20. But for virtually every human on this planet who wants to live independently, that number is about 15 or 16. So the argument I would have is everybody should have as high a VO2 max as possible to give them as much optionality as possible in the inevitable state of decline. And I think that is true for mitochondrial function. Two points. Going back to the car analogy, you should be able to go 45, 50 miles an hour. If you have a car that's below that, that's not a functional car, even in the city of Chicago. Well, not only that, you don't want to be at the red line going 45 to 50 miles per hour. To begin with, because it's going to go down to 20. Violent agreement on that, okay? My point is, I am not convinced whether mitochondria to go 200 miles an hour, yes, but whether mitochondrial function becomes rate limiting. I agree with you. I agree with you. I don't know that. I don't know that, right? So you made the analogy, you can go 100 miles, but we want you to go 200 miles now. And guess what? We're going to boost your mitochondria to do that. Fair enough. And I'm like, you know what, Peter? I'm happy. I just need to maintain 100, because I'm going to have a fall in it. But even that fall that happens, is that really because of mitochondria, or is it because of neuromuscular- Totally agree. And that, to me, is the exciting question. Because I think on some areas, I think when it comes to maximum aerobic output, I think the data look pretty clear that it's actually cardiac output that becomes limiting. Which means it is heart rate and stroke volume and contractility. Those are going to be your limit at max output. When that escalator, is broken, and you're late for your flight, and you have to carry a suitcase that's 27 pounds and sprint up three escalators, that is going to come down to cardiac output. But when it comes to more sustained aerobic efficient activity, yeah, I don't know how much of it is cardiac output versus mitochondria, et cetera. And the reason I think that the mitochondrial topic is so interesting is because of how frequently it is implicated in metabolic disease. And that's why your life's work is a very, very important part of your life. And that's why I think that's a very, very important topic. And we're going to talk about things like all of the potential targets, including drugs like metformin. So I don't want to spend too much time on the theoretical, but I want to set the stage for people. Why is this such a fascinating question? I like this VO2 discussion, because we're working on exercise now, too. Finally, I think I probably have to thank you for that. And just muscle health in general to ask this question. But what I would say is, yes, could we find therapies to boost our mitochondria so we look like that cyclist? Peter can maybe take a supplement or something or a drug that helps increase that efficiency. I just want your opinion on this. All I'm arguing is, as we normally age, does the mitochondria become limiting for daily activities or even mild exercise to have a good quality of life? I'm not convinced of the latter. Because other things like what you said about stroke volume, oxygen delivery, take your statins. You don't have atherosclerosis. You've got good pipes giving you oxygen. That's not good. And I think there's a component to this, which is it depends on the individual. So there was a study that came out somewhat recently that looked at VO2 max limitation in unfit and untrained individuals. So it was a longitudinal study that followed unfit, untrained, non-exercising population. And in those individuals, VO2 max turned out to be more limited by peripheral oxygen transfer. And you might look at that and go, oh, my God, that's really interesting. But then when you read the fine print, you realize that doesn't apply to anybody who's exercising. Or training. Once you start pushing the envelope a little bit, cardiac output becomes rate limiting. And so I do wonder if on the mitochondrial function side, it also may have implications under, well, if you have a disease, if you have one of these many diseases that directly implicates mitochondria, the answer is this. If you are a very healthy, active person, the answer is this. And if you were a sedentary person, the answer is that. We have to figure out all those things. I mean, we can both agree the three inputs in the system, the heart stroke volume, how much is pumping, the blood going to the right place, and mitochondria extracting it. And it could be in three different populations. You have three different problems. By the way, I should be a little more accurate. When I say cardiac output, I'm including hemoglobin in there. It's really oxygen delivery. So if you have a high cardiac output but a low hemoglobin, it's all for naught. But yeah, yeah, yeah. I like what you just said here. We could have three different populations. And what's limiting is the delivery, but not the mitochondria, or the mitochondria extraction, but not the delivery. So let's pivot and now talk a little bit about dysfunction. And let's talk about it in the broadest sense we can, which is, do we believe that mitochondrial dysfunction is an inevitable consequence of aging, given that it is designated as one of the OG hallmarks of aging? Yes. I am skeptical. A few times I'm going to bring up conflict of interest. I think it's important to say your conflict of interest. It is almost a conflict of interest for me to say that. If I want to make a living, I should tell people mitochondrial dysfunction is why you're aging. And lots of people do. I'm not so sure. Again, not in a diseased person. We can talk about the disease. We're talking about a normal, healthy person. Let's talk about you and I. We're old men now, relatively speaking. We're 10 years older than when we first met, okay? I agree. The question is, going back to this analogy, if you have to go to 70, 80% of your mitochondria for it to have a cell not work properly, do you ever get to that? The hallmarks, by the way, they're instructive, but they're misleading, all the hallmarks. They are what's called a sufficiency experiment. What does that mean? That means if I take a mitochondria and I perturb it, so a healthy mitochondria is this high, and I make it here in a particular organ or an organism, it will degenerate and maybe it'll age or look like aging. You could do it with a lysosome. You could make lots of cells senescent, but that doesn't mean that normal aging, that's what happens. In other words, is mitochondrial dysfunction necessary for normal aging? It might be sufficient. So people have done what's a sufficiency experiment, which is they take mitochondrial DNA and they cause mutations in them genetically. So the mouse gets mutations only in their mitochondrial genome. People have done it with the nuclear genome. In both of them age, I can tell you the new genomes are going to be going to be going to be going to be going to be new nuclear genome mutations looks more like normal aging. Mitochondrial ones that they've generated, and normal aging will have this much mitochondrial mutations, let's say, you have to go almost tenfold higher mutations in order to start to see that organism degenerate in a mouse. And it doesn't even look like a normal aging. So let me make sure I understand that and replay it back to our listeners. We're talking about something that we're taking for granted. I'll just state it quickly. We have two genomes. We have a genome within the nucleus. That's the one we are almost always thinking about. But then the mitochondria have their own DNA. We should just make sure everyone understands that. Okay. If you take the DNA in this cell, what we're calling the nuclear genome, and you apply mutations to it, because as we age, we are acquiring mutations. You're saying you're able to replicate an aging phenotype by adding mutations to the nuclear genome. Not me. This is the work of others in the field. Let me be very clear. None of this. The field is. Yeah. They've got some mouse models where you have some nuclear DNA mutations at the same level as a normal aged mouse would. And they have hallmarks of aging in that mouse somewhat. Conversely, when you take the mitochondrial DNA, not you again, but when the field takes mitochondrial DNA and they insert mutations. And let the mouse age. They do not see the same aging phenotype, even when they make those mutations. They're at a rate of 10x what occurs normally. Right. So normally you'll have this much mitochondrial mutations. If make a mouse as early in life that has the same amount, nothing happens, nothing happens. And then you get to this huge threshold, boom, you start to see this mouse degenerate. Some of it looks like aging, like hair loss, for example, but some of it doesn't. And some of the pathways that get activated, so we took a cell recently called the microglia, which is a very important cell for inflammation, for lots of things in the brain. If you knock out mitochondrial function in that microglia, at one year, it doesn't look like an aged mouse. What if the dysfunction of mitochondria does not come through genetic mutation? What if it comes through proteomic degradation? What if it comes through membrane permeability? What if it comes through anything that is downstream of transcription? What if it's a translational problem? Just to back off, the reason we went through what mitochondria functionally do, is you can now go back and your three hierarchy thing, do you lose ATP capacity as we age mitochondria? Probably not. Do we lose the TCA cycle, maybe not making enough metabolites? Likely not. Do we lose some of the signaling? So in other words, instead of making too much H2O2, maybe we're not making enough in a certain immune cell. Or we went through this whole, how is mitochondrial DNA might be leaky? If it is leaky, you're not going to pick it up in the first two parameters of ATP TCA cycle. It's a different thing that's happening. So I would define if mitochondrial dysfunction is related to aging, it isn't simply about running out of ATP or running out of metabolites. It could be this miscommunication. It's not the glib, obvious first and second order deficiency that probably gets us into trouble. It's one of these fourth order terms that is much more nuanced at a cellular level. We're trying to figure that out. So I can tell you, when we take mice and we genetically don't let them make H2O2 enough, their immune cells don't work, for example. They don't differentiate properly. Now, does that happen as we age? Our ability to regenerate and all of that doesn't work as well. Is that because we're not making enough H2O2 from mitochondria or something else? It's an open-ended question, but I'm examining mitochondrial dysfunction, not the lens of ATP, not the lens of just making metabolites for growth, that maybe not enough. For example, alpha-ketoglutarate levels go down as we age. So is that somehow causing problems for DNA methylation, which could cause, obviously, age-related defects? So there are so many compounds I want to talk with you about. Can we turn to metformin as the starting place? Yeah. Okay. So you're one of the people who knows more about metformin than almost anybody. Listeners of this podcast have heard me talk about metformin quite a bit. I've done many interviews with you. I've done many podcasts on it. I've had Nir Barzalai on at least twice. I've also been on Andrew Huberman's podcast where I did a very, very thorough journal club looking at both the Bannister paper and the Keys paper, which were really the two massive epidemiologic studies. The Bannister paper was the one that really got people excited about metformin as a geroprotective agent. This is the study that looked at a cohort of the population and made an observation that non-diabetic people not taking metformin, which is a very important metformin, had worse outcomes than diabetic people taking metformin when it came to cancer. That basically got the idea going that metformin could be protective of cancer. Roughly eight years later, a more, in my opinion, rigorous study came out that challenged those findings, ran the analysis two ways with and without a statistical tool used by the first analysis, and it didn't find that at all. And truthfully, I found the second study more convincing. That doesn't mean metformin doesn't work. It just means that the epidemiologic argument was more shaky. What about the phase three clinical trial in breast cancer that failed? Yeah. And then the prostate cancer trial. Let's talk about them. But I agree with what you just said, by the way. Yeah. So people have heard of metformin. I don't think there's anybody listening to us that hasn't, but I don't think a lot of people maybe understand the complexity of that drug and how many different things it does. So can you explain to people how metformin works? Yeah. Well, again, work in progress. To the best of our knowledge. Yeah, yeah. You and I have talked about this before. Let's just talk about any of the supplements we'll go through or any of the drugs. Most of them you take oral. Let's stick with that. The first pass is the gut. So with metformin, it goes in the gut. And people have done this with C11 PET imaging. They can see the gut light up, the intestines, the colon light up. Then it goes to the portal vein to the liver. Then it goes, there's the kidney, and then it gets excreted out in a couple of hours. It doesn't get in the brain. It doesn't get in the heart. It doesn't get in the muscle. It doesn't get in the liver. It doesn't get in the blood. Why is that? Because metformin needs a transporter, the organic cation transporters. There's one, two, and three. There's some other ones as well, but let's just keep it simple. The gut ends up taking it up quickly, but releasing it in the portal vein slowly. So the highest concentration of metformin up to a millimolar, wow, is in the gut. By the time it gets to the liver, it's less, 50 micromolar, 100 micromolar max. By the time it's in the blood, 10 micromolar. We have seen some immune cells, macrophages and T cells, certain types, and other people have noticed that they will also take it up. That you can't have the resolution when you do a PET imaging analysis. But this part is really key, and it's going to explain the cancer data in a second as well. You need the transporters. So the highest concentration is in the gut. The other thing is- And everything after the gut. So when the gut absorbs, so the gut has the transporter, obviously, but does it otherwise diffuse into the portal circulation, or does it also require the transporter in the portal circulation? It requires it to take it up. It needs a transporter to dump it out of the enterocytes. So the metformin gets accumulated in the intestine or the colon cells, but it takes a little bit longer, less transporters to release it into the portal vein. Because that's a huge drop to go from one millimole to 50 micromole is a 20X drop. It's estimated as high as one millimolar, and that's a huge drop in it. Here's the experiment that got me super excited about why the gut. So the original idea was metformin goes in the liver, it decreases hepatic glucose production. So your liver, as you pointed out earlier, can make glucose. It's largely an anabolic organ. And so what people, the oncologists have known this, and you probably remember this, that if you take metformin, and God forbid you have cancer, they tell you to get off it. Because they use an FDG PET, a glucose tracer, that they can- Easily see that lights up. Well, if you take metformin and you give that glucose tracer, guess where it lights up? One place, the gut. So why would it light up in the gut so much? A, it's at a very high level. So every cell which has a mitochondria, if I inhibit the electron transport chain, the thing that's generating ATP and consuming oxygen, to compensate for it, it takes up glucose and goes through glycolysis to make the ATP deficit. So if you have a mitochondrial toxin, the only way you survive is by sucking up as much glucose, running it through glycolysis, making lactate, anaerobic fermentation. So why would that happen? Well, about 25 years ago, biochemists noticed metformin can inhibit mitochondrial complex I. So this is the complex I that takes the NADH and makes NAD to keep the TCA cycle and does a lot of other signaling functions. So metformin, this is interesting, at least in that tissue, might- It might decrease mitochondrial NAD levels and increase mitochondrial NADH levels, the opposite of what NR is doing, or the NAD supplements. Or what people want NR to do. People want NR to do. And so Colleen Rezic in my lab, I want to give some shout outs here, and Zach Zibo, who's been doing the recent work on it. Colleen made a mouse where she took a yeast protein from yeast. Mammalian mitochondrial complex I is 45 subunits. Some are nuclear encoded genes, some are mitochondrial. It's the largest complex. It looks like a boot, okay? It's huge. The yeast has a single protein, which can work as a homodimer. The same protein comes together, and it could do the same function as a mitochondrial complex I. In other words, take NADH to NAD, pass electrons to the rest of the transport. So there's some things it cannot do, but let's leave that aside. But basically, it's a bypass. So if you get rid of mitochondrial complex I, in many cases, it's a bypass. So if you get rid of mitochondrial complex I, in many cases, this yeast protein can overcome its loss. So we've done this in dopaminergic neurons. We lose complex I, and genetically, we put this protein, it's called NDI1. Guess what? The neurons are fine again. So she made a whole mouse, which expresses the mammalian complex I and the NDI1. And she just asked, if I give metformin, what happens? Metformin typically lowers the glucose levels. If NDI1 is there, it's largely refractory. Arguing that complex I is the target. And do we think that the majority of this is happening in hepatocytes? Well, she did a whole body. So Zach said, well, the largest place it's going is in the gut. Let's start with the gut. Why the liver? So he takes the same NDI1. He puts it only in the gut. Nowhere else. First, he looks at that FDG PET scan. And in a mouse, it's huge with metformin, completely abrogated. So that implies that metformin must be inhibiting complex I, because NDI-1 cannot be inhibited by complex I. so a normal mouse will have all this glucose uptake in the gut but if you have the yeast complex one which is refractory to metformin bingo it goes down and so what he noticed is people have seen GDF-15 goes up with metformin I don't know if you know that so GDF-15 it tells you not to eat it's an appetite suppressing not at high levels GLP-1 goes up all from the gut there's one called LAC-FE lactate and phenylalanine all of these abrogated we haven't done the colleagues doing the liver experiment to see how much the liver contributes by the way our paper the second one I just talked about the intestine it's a pre-print that anyone can see we'll link to it yeah but I'll tell you something that Zach noticed which I think I give him a lot of credit for here he was looking at metabolomics of people in metformin do you know what the number one metabolite goes down when people are on metformin citrulline citrulline and the sports junkies know this citrulline is taken up goes in the kidney becomes arginine and then the arginine can be used by the rest of the body for nitric oxide and keeping you vasodilated so you can either absorb citrulline or you can make citrulline citrulline and you make from ornithine which requires mitochondrial ATP so what he found is that in the intestine when mitochondrial complex was being inhibited those intestinal cells didn't make enough ATP and citrulline levels dropped in the blood the NDI1 the citrulline levels didn't drop why am I making a big deal of citrulline because there is a study out there which argues that you should take metformin while you eat and we'll get into in a second but long-term metformin use might compromise the exercise induced vo2 max and hypertrophy and potentially hypertrophy I would argue that maybe might be because of the citrulline it doesn't get into the muscle but I can imagine lowering your citrulline so I just wonder so you're saying if you're taking metformin citrulline the without it what it might be doing is inhibiting vasodilation which inhibits the delivery of oxygen oxygen and or altered other nutrients that are necessary for anabolism the other one is b12 so b12 levels go down with metformin so people should take b12 people don't quite understand why but the idea is that the gut doesn't absorb it as well but that's why it's so important to take b12 because it's so important to take it and it's so important to take it and it's so important to take it and it's so important to take it and I think it's amazing Peter if you think about metformin when you and I started talking about it we talked a lot about the liver effects but the gut I mean whether it's the citrulline effect whether it's the b12 effect oh I didn't even say people on metformin have a very positive microbiome the immunosophilia microbiome again I'm not a microbiome but it's always positive whatever the good microbiome is metformin gives you that again a gut effect now how does that work I don't know but my point is what happens when you give people intravenous metformin where does it get taken up liver more so in the liver not in the gut at all because the gut's not going to see it it's not going to see as much of it it gets more liver and by the way you know the new metformin the delayed release one hangs out in the gut even longer does the muscle take it up with intravenous I don't know that so that would suggest assuming it does not it would suggest that any negative impacts of metformin on exercise performance probably are circulatory or they're basically coming from some metabolite right and I'm going to argue maybe b12 because if you have b12 deficiency you make something called methylmalonic acid which can be a complex to inhibitor in the mitochondria I'm not saying that's the mechanism but I'm thinking exactly what you are that it's got to be something circling most of it's in the gut some in the kidney in the liver something from those organs is affecting I don't think this idea oh you have a complex one inhibitor now in the muscle and that's why you're vo2 and by the way the data on the vo2 max and you should look at it yourself carefully it's not like it completely abolished it and it's a short-term study to me the really important question is are there giro protective benefits to metformin let's examine the state of the science on right so if you take metformin at the time you're having a meal and we've seen this in our experiments the postprandial after eating a meal you have a glucose spike I'm sure people glucose monitors can see that spike and depends on what kind of meal metformin abrogates that and that's again complex one to independent so there's pretty good data to suggest that all-cause mortality is somewhat linked to those spikes I mean there's some studies out there but a carbose does the same thing it does and a carbose did extend life in the ITP Richard Miller's but metformin did not both were delivered in the chow so why do you think a carbose which clearly does that and metformin which might do that didn't work I don't have a good explanation to it not that that was being measured right they didn't have glucose monitors but I would argue that now that we can clearly see this glucose spike happening lots of people observe and metformin can abrogate it I wonder if that's a good tool for people to use I don't know what you think of that I'm just thinking aloud you have a glucose monitor or you do it for three months you get a good good increase decrease you get some I mean look there are three glucose regulating drugs that went into the ITP there's Kanaga flows in the blood and the blood flows in the blood and you're A-carbose and metformin. The way the ITP is designed, the drug is always in the food. So the vehicle of delivery is always the same. Canagiflozin and A-carbose worked. Not many drugs work in the ITP, but those two did. And metformin did not. And so what do you think explains that difference? I don't have a good explanation for that. The Canna drug, some people argue is a complex one inhibitor too, by the way. In addition to being an SGLT2 inhibitor? Yeah, yeah. There's some papers on it, and I think it would be good for us to run those through our NDI1. I don't have a good explanation for the mice. All I'm just saying is that in humans, that glucose spike can be reduced by metformin. I think you would agree with that. People should do that study carefully. They're small studies. Anyone can do it who's on a glucose meter who's taking metformin. And anecdotally, when I ask people, they go, oh, yeah, yeah, when I take metformin before a meal, that's the key. How long before? 30 minutes before a meal, probably. Within 30 minutes, it's in the gut. And the data on the pre-diabetes people, metformin is much better than the full-blown diabetes. It always has been. If you're on full diabetes, we know the Gs, GLP-1, the triple G that'll come, yeah, and then the SGL-2. So you and I would both agree it has some beneficial effect in keeping your glucose level, right? I completely agree with that. I'm going to go through the four horsemen now. Yeah, and I think that metformin should always be considered a first-line drug in people who are pre-diabetic or very insulin-resistant. But the real question is, should a person who's insulin-sensitive consider taking it for these geroprotective purposes? Right, right. So I'm going to just argue that you get a better microbiome and you get a better glucose lowering if you're on metformin. I will accept the second. I will plead ignorance on the first because I don't know what a better microbiome means. I don't either, but there are these microbiome communities that say this is a that the microbiome is 10 to 1 your normal cells and blah, blah, blah. And all of that stuff has been proven to be wrong. I know. That is not the reason to do it. I'm just saying, and because it's in the gut, I always get people saying, the whole thing is in the gut now. Is it going to make my gut leaky? What I'm saying is whatever that is, it's not affecting that in a negative way. I'm going to assign very low confidence to that point because I think that is still very, very foggy. But the second point is true. It lowers blood glucose. Okay. But you have to understand, Peter, if I'm going to talk about the gut these days, the large public is dying to know, will it give me a bad microbiome? I want to make sure we're not feeding into, yeah, I just want, I don't want to feed into the scientific illiteracy that has become the way we talk about the gut. Good versus bad, like good cholesterol versus bad cholesterol. People still say that it is a meaningless concept. There are microbes that generate butyrate, which has been shown mechanistically to be good. Those microbes are increased when you take metformin. Put it that way. But the second thing is cancer, which is where you started. So it's failed. We can both agree on that. On clinical trials, there's always some signal here and there. So the prostate one, and there was a subset of patients that it looked pretty good. But generally, let's just say it's a negative. So why is it a negative? So we did an experiment mechanistically where we took cells that were very sensitive to metformin, and we put it in a mouse. The tumor grew. We gave the mouse metformin. The tumor grew. The tumor grew. The tumor grew. The tumor shrank. And that tumor, we put that yeast NDI1 back in. So it would be refractory. And guess what? The tumors came back. So again, mitochondrial complex one inhibition by metformin explains the anti-cancer effects. I think that part is more widely accepted. What was the cell of origin of that cancer? That was, we did it in two. We did it in a lung cancer, and we did a colon cancer. And the metformin was delivered orally in both cases? Orally. Again, orally, both cases. So how do you think it made its way into cancer? Yeah, I'm going to tell you in a second. So what we had noticed was not only we, many people had noticed that if I took 60 cell lines, 10 cell lines, one or two would respond in culture. The other 10 wouldn't care. I could go to 100 millimolar, they wouldn't care, barely. A student in the lab, Karthik Vasan, he did a simple screen. He took a very sensitive cell line to metformin in culture, the same one in vivo that in a mouse, and he took a very sensitive cell line and he added metformin to it, and it killed that cell. Okay, he added it a dose, it killed it. He basically, using CRISPR, the CRISPR-type technology to knock out every metabolic gene. So he's got 3,000 different clones now with all the metabolic genes knocked out. 2,000 of them, like 1,000 of them are so fundamental for life. Incompatible. Incompatible. The other, I don't know, I don't remember what the numbers were. Let's say there was 1,000 that lived. And then he asked, if I give those metformin, who lives? One guy lived. One clone lived. One guy could live. It lost the organic cation transporter. So it couldn't bring metformin into- The plasma membrane transporter, if you lose it, it laughs at metformin. It doesn't care. Okay. Why is that important? Wouldn't it be nice to do a clinical trial based on whether you're positive for that transporter or not? Do we know that when we screen human cells, can't we screen for that cation? At least in the, I mean, that should be knowable. There's three of these transporters, aren't there? Three transporters. Yeah, yeah, yeah. Do all three of them transport metformin equally? Seems like- At least in the cancer one is organic cation transporter three. But your point is, can you not come up with a diagnostic test? So I'll play it one step forward. It's very important to know how frequently that's mutated, because if that's mutated a lot, it could explain why you have failures in clinical trials. If it's mutated very little, that would suggest that that's not the reason. In other words, it's not the failure to deliver metformin sufficiently to the tumor that causes the failure. Right. But what I'm going to argue is tumor cells may not even have it to begin with. You're saying they lose them? No, no, no. So the experiment that we did, we made genetic knockouts in an unbiased way. And we said, let's lose in each cell individually- But the cells were what to start? They were positive. They were positive, but lots of them are not positive to begin with. Let me back up for a second. Are you telling me right now, you know my liver has these cells? Yeah. Let's just assume I don't have any mutations. You know my gut has them? Kidney has them. My kidney has them. You don't know if my pancreas has them? No. Most of the cells don't have high robust organic cation transporters, or else they wouldn't in high levels of it. And what I'm saying is when you look at the cancer profile- Yeah, but you said it only gets in the blood at 10 micromolar. Right. So you have this huge drop-off when you go from gut to liver to blood. So if the blood only has 10- 10 to 20 micromolar. Sure. If the gut only has 10- Maybe at peak it goes a little higher. Okay. But still, is that even enough to get it into cells should they have the transporter? Yeah. So when we've measured it in the tumors, as you can find it, and more importantly, the best experiment we can do is when we give NDI-1 and we abrogate the effect. So there was sufficient amount of metformin- So you see a big enough delta with the two different complex ones, even at that low a delivery? Well, 10 micromolar gets enriched 100x in the mitochondria. If it gets delivered because of the potential, so it's cationic, metformin is positive, and you're pumping a negative. Electron transport's working, it's pumping negative, and you bring it in. So people have estimated anywhere from 100 to 500x metformin accumulation in the matrix where it binds to complex one. But again, we can argue about, did it work? You're saying we don't even know if a breast cell has this transporter on it? No. What I'm saying is we didn't go back and try to figure out whether breast cancers that were given, we didn't stratify them by organic cation transporters. No, no, no. Totally get it. But I'm saying in the wild, don't do that. I'm saying in the wild type, for a woman who's listening to this podcast right now, it's likely that her actual mammary tissue does not contain the transporter. Probably doesn't. So then it seems very unlikely that when she develops cancer, that it's somehow going to randomly mutate in developing the transporter. Right. Not mutated, but maybe the oncogenes, because remember, these transporters are not designed to bring in metformin. They do have other functions to bring in other organic cations potentially. I don't know which- It's active? It's ATP exchange? I don't actually know that. Okay. I actually don't know that. How positive is metformin? I think serotonin, and I don't remember this, Peter, I want to say there's something important that it transports. Okay. I heard it's at a low level. Forgive me. But the simple point being is that we didn't go back and stratify based on the transporter. EGFR inhibitors are given to someone who has a mutation in EGFR. Herceptin is given, going back to the mammary tissue, breast cancer, to HR2 positive. So we didn't do that. Another way you could do it is let's take a tumor that is not FDG positive for glucose. It doesn't take up a lot of glucose. There's many tumors that don't, as you know. Now we give the patient metformin. If the tumor starts to light up with glucose, you bet metformin got in and inhibit mitochondrial complex 1. You could stratify it based on that, right? Or is your tumor metformin responsive by FDG-PET, low versus high? Is it your hypothesis that if metformin is going to have efficacy in an oncologic setting, it's going to do so through mechanism number two, going back to the original four things we talked about, where mechanism number two is by inhibiting complex 1, it's not so much that it's inhibiting the ability of the tumor to generate ATP, but more importantly, it's the ability of the tumor to generate building blocks for cellular growth. It's the anabolic targeting. Absolutely. Absolutely. Because that electron transport makes the TCA cycle go, oh, and you inhibit electron transport, TCA cycle, which makes them metabolize for growth, are lowered, and now you can't grow as well. But all of this depends on metformin being efficiently coming in through the transporters, probably through the mitochondria. We've been trying to find how it gets into the mitochondria. We haven't figured that out. Really? Yeah, we haven't figured it out. We don't know how mitochondria gets from the cytoplasm into the actual inner matrix. I don't know. I don't know how metformin gets into the mitochondria. I know how it gets from the cell membrane. It needs those organic cation transporters, one, two, or three. Yeah. Actually, the screen was designed to try to figure that out. We didn't, but we stumbled upon something simpler. And this is just a very super naive question, but are we at the point technologically where we can do time-lapse electron microscopy and actually watch something like metformin travel throughout the cytosine? I don't think so, but someone did this fancy cryo-optimization. Yeah. It's called cryo-EM technology, which I'm not familiar with. It's the best of the structural. And now they can see where metformin binds to complex I. That's assuming it's already inside. It's already inside. Yeah, yeah. This is different, but it's pretty cool. They figured out in this BOOT45 subunit exactly the binding sites of metformin. Very cool. And they also made a point that it didn't inhibit any of the other complexes, because some people argue complex IV might be a site. I don't buy any of that, and nobody does in the field other than a few people. But I'm open to it. Okay. I'm open to it. Complex I clearly is inhibited by mitochondria. This NDI-1 is a good way to. To test it. to test the necessity of complex I inhibition. So going back to should you and I take metformin, okay, it can lower my glucose. That's not a bad thing. The cancer effects, well, you could argue that for us, prostate cancer, that if our prostate cancers, for whatever reason, God forbid, are lesions, if we were to get them as we age, they happen to be organic cation transporter positive. Big if. Then maybe there's some efficacy there. But is that reason enough? And even if you deliver it intravenously to put a higher concentration in circulation, it's either binary. Either you have the cation transporter or you don't. Even if you drove the blood concentration up a log, you wouldn't. No, no, no. Exactly. Because we gave quite a high metformin to kill in that screen. When that cancer cell lost the organic cation transporter, it became totally refractory to metformin. So then is it your. Is it your suspicion that if you took a woman with breast cancer or a man with lung cancer, and you could screen their tumor, and indeed, by some good fortune, they had the OCT on it. OCTs, yeah. that metformin would be a potentially potent anti-tumor drug? Potent is a famous last words, yeah. Yeah, exactly. How much will it prevent proliferation? It will not decrease proliferation, but the best thing it'll do is they'll stop consuming oxygen and the local oxygen concentrations will start to increase. increase in a tumor, which would make it better for radiotherapy and immunotherapy. One of the challenges in immunotherapy, there's many, but one of the key ones is the hypoxic tumor microenvironment is very immunosuppressive. So anytime you can increase oxygen levels, that could be helpful for radiation, as well as that, along with not making the building blocks. But we don't screen for any of this stuff. And because metformin is so cheap, who's going to go and do these studies, go back and do all of this? But I guess from a geroprotective, maybe you take it just in case. So this is more bullish than where you were eight years ago. Or seven years ago, I said, are you going to take metformin? And you said, no, I need to see more data. Yeah, yeah. So at least I know now why it wouldn't work in cancer and why it may work in cancer. I have a good explanation for it. I got a good explanation for the glucose lowering. So I'm going to give you the third one. This is the one every day I wrestle with, Peter. Should I do it? Should I? Inflammation. Inflammation. I take a statin now, even though I don't need to. I take a very low-dose statin. At 50, I decided to go to my doctor, who's a great doctor, also with Indian genetics. I had pretty good numbers. I'm listening to you, of course. So I have something for that. I exercise. I have something for my muscle. I'll be social, et cetera, all the sleep, et cetera. But for inflammation, and I've been thinking a lot more about inflammation. So the city of Chicago, which had terrible pollution for a long time, really cleaned up its act the last 20 years. Except this past year, thanks to the Canadian wildfires, it's raging. But at one day, I think we were the worst in the world. Trust me, the last 20 years, you can look at the data. we're not a terribly polluted city, at least where I live. We've done trees on top of trees on homes, et cetera. We've done a lot to make ourselves not. And now we have this. What are you going to fight against pollution, pollution-induced inflammation? So my friend Scott Buttinger, Gokhan Mutlu at Northwestern, years ago, they were giving Beijing-level pollution to mice. And one cytokine goes up robustly in humans and in mice, IL-6. And IL-6 makes you prothrombotic. Therefore, you're susceptible to cardiovascular injuries, an MI, for example. Okay. They started taking alveolar macrophages and giving it low-dose pollution in vitro. And they noticed that the pollutants, this particulate matter, these small particles, were going in the mitochondria and increasing that H2O2 signal. And they could show that H2O2 signal was responsible for the IL-6 production. So it's pollution, particulate matter pollution, mitochondria. Increasing H2O2, not to kill, as a signal for inflammation. And by the way, does the pollution have to be PM 2.5? I think so. It was that one. That's what they did. Yeah. The crazy thing is, I was like, "Oh, Scott, you got to put metformin." And he goes, "What do you mean?" I go, "Metformin inhibits complex 1, and it'll prevent the H2O2 from being released." He's like, "Okay." So they did it in vitro and in vivo. It's a paper in Cell Metabolism. And beautifully, they could show in vivo. Giving it in the drinking water, that it lowered the IL-6. And is that because the liver is making. The alveolar macrophages. It's the alveolar macrophages? It got to the alveolar macrophages. They took it up, because we could see in the alveolar macrophages. How are they getting the metformin? They're taking it up. Out of the blood? Out of the blood. So they have. They had the transporters, but they're good at, I think, at also taking up stuff. What we want to do is put NDI-1 back in those macrophages to definitively show. So it did take it up in an inhibit complex one, because it could have been an effect from somewhere else. Maybe the gut, everything. But the key point is, we're still working on the mechanism, Peter. And we've done, by the way, we've given flu with metformin. There was always a COVID signal with metformin, decreasing the inflammation. So in mouse models of SARS-CoV-2 or influenza, when people give drinking water metformin, it lowers the pathology. But my simple point was, I'm going to be exposed to pollution. Again, there's no human data with metformin and pollution. Measuring CRP or something like that for a couple of months and seeing if it was lower at a population level. Do you think IL-6 would be more sensitive than CRP? I think CRPs would be equally sensitive, I think. But again, people just haven't designed the trials correctly to think about this. So here's the last one about inflammation. Do you know what clonal hematopoiesis is? Yes. So this is, as we age. But tell people, because it's an important part of heart disease. We probably don't spend enough time talking about it. Yeah. So as we age, our hematopoietic stem cells, which make all our blood cells, including our T cells and our B cells and our red blood cells and our platelets, as we age, those can pick up a particular mutation, and actually mutation in the enzymes that run epigenetics largely, and they become rogue clones and they overtake. And they somehow contribute to cardiovascular disease, definitely inflammation. And the level of clonal hematopoiesis can range from 3 to 20%. And of these rogue clones taking over as we age. So UK Biobank did this study. They looked at clonal hematopoiesis, and they somehow, and I'm not an epidemiologist, controlled for diabetes and everything. People on metformin had lower incidence of clonal hematopoiesis, 450,000 UK Biobank. The same people made a mouse model of clonal hematopoiesis, and they gave metformin a decreased clonal hematopoiesis. How much? Significantly. Significantly. It was quite remarkable. Here's the best part. Some smart reviewer said, "You should put NDI-1 and show me as complex one." And it was. So in other words, metformin binding to complex one prevented those clones from outgrowing from the mechanism you pointed out because the building blocks weren't there. But again, how are we getting so lucky that these cells have OCTs? To be honest with you, the dosing they did was 50 micromolar in vitro to have some of these effects. I was shocked. And they were doing this in human cells? They did it in mouse cells. Three papers came out at the same time to the same conclusion. So speaking of reproducibility, three different ways. Two of them were in nature. The other one was in nature communications. All three of them said, "If you inhibit electron transport chain, you can prevent clonal hematopoiesis, and the best drug that is safe is metformin." So Peter, let's just wrap up the metformin. There's a couple of lessons in the metformin. On the mechanism side, and we're going to get into some of your other favorite supplements, perhaps, we should first think about when you take an oral supplement or an oral drug, where does it go? Does it accumulate everywhere, or does it only go certain places? The second thing we have to know is, what is its target? I've argued it's complex one because I've made a complex one that is refractory to metformin binding, but works like complex one. So someone should always show me the target and make that target work better than the other one. And if I do that, I'm not going to be able to find the target. I'm going to be able to find the target and make it work perfectly fine, but not bind to metformin or whatever other drug or supplement. And the third one is, maybe you don't even care about where it goes and what it binds to. Does it work in humans? Not in mice, only. And so the data suggests, you tell me if you agree with this, in a normal person, it'll keep your glucose levels down. If you take it before a meal, not a bad thing. If you get lucky, if it has that transporter, then it will persist. Perhaps lower the cancer clones from arising. And if you're lucky to have that. The third one is, clonal hematopoiesis that happens with age, it lowers, according to these studies. And in our study with pollution, and then some studies that people have done with T cells, it seems to be a low anti-inflammatory agent. So is that enough for people to take it? So what are the risks? The risk is B12 deficiency, but you can fix that. The other one is citrulline. You can easily take supplement for that. People get nausea. People get nausea. So people, sometimes people don't take it, but many people don't. So that's where we're at. Do you think it cross reacts or interferes with other glycemic agents such as GLP-1 agonists? Yeah. What do you think? I've asked people that, they say no. I don't think I have an informed enough opinion. I just don't. Yeah, I don't either. There are people who do both, as you know. I just don't. So it's the inflammation part, because I'm not going to take an NSAID. I'm not going to take Aleve every day. I take it sometimes. It's pretty potent. Then the question becomes, why did aspirin fail in the ITP? Why would COX inhibition, which should be reducing inflammation, had no impact on- Well, it reduces different kinds of inflammation, perhaps. We can show metformin inhibits IL-1 beta, IL-6. So what would we need to do in humans? I've lost track. Is TAME happening? What's going on? I don't know. I don't know. But again, the cancer trials, the TAME trials, every trial in metformin, because it's cheap, it's been guided. Smartly, by whatever data is in humans, could we redo these trials based on mechanism, mechanism being the insights we have now? Put glucose monitors just to see over a year how well did the metformin that people took, just to know whether it did anything. Maybe it doesn't. Maybe some people, for whatever reason, it doesn't get absorbed. Maybe their transporters are low. So have some indication and maybe measure CRP or some other measure clonal hematopoiesis. There's ways to do that. There is all of this sort of stuff. As far as the cancer, that's almost impossible. You're just taking it, something that may help protect against, or if you get an early lesion, it might slow it down. But I like the inflammation and the lowering glucose as the two actionable ones. And is there anything else that really can do that? Well, I think if you're lowering CHIP, that's pretty interesting. Yeah, yeah. We'll have to see how well that manages. And that hasn't been demonstrated in human cells yet? Well, it has. And it's been also demonstrated in the UK. The UK Biobank has just a correlation. But it hasn't been proactively tested in humans? No, no, no. You mean as a clinical trial? No. Someone used to do that, but it'll take five years. But that would be a very interesting trial in a high-risk population. Yes. You take a high-risk cardiovascular disease population that is otherwise well-managed. Because one of the questions I find interesting in ASCVD is, I'm interested in the topic of residual risk. So why is it that some people can have significant risk, then you manage them well with blood pressure and lipid control, but then they still progress, disease progression occurs at different rates. There's some residual risk beyond the ApoB and beyond the hypertension, and let's assume they're not smoking. And how much of that is CHIP-related? And if you can find that population, and you do an RCT there with and without metformin, and you track the hematopoiesis, the clonal hematopoiesis question, I think that could be very interesting. Yeah. By the way, speaking of heart disease, I think that's a very interesting question. Speaking of heart disease or heart failure, speaking of metabolism, one of the best new drugs are these SGL-2 inhibitors. The SGL-2 is basically in the kidney, so you pee out, they call it sweet pee. The urine, you just pee out the glucose into the urine, and that somehow is communicating to the heart and telling it, a failed heart, that you're good to go now. The idea that heart failure is due to mitochondrial dysfunction is the one I really have my doubts on. I just don't think the evidence really points to that. You can make a mouse model where the heart fails because the mitochondria are failing. Right, but that doesn't mean that's- That's what's happening. And the results are mixed in humans, but the best evidence to is that you could put somebody on an SGL2 inhibitor, it somehow globally reprograms their metabolism. And that's a very loosey-goosey non-mechanistic term. Maybe increases a little ketones or fatty acids, but their heart works fine now, which means there could not have been intrinsic mitochondrial defects. Because if there were, SGL2 inhibitors wouldn't work so well. Now, I want to talk about a whole bunch of supplements that get talked about a lot. Before I do, though, I just want to go back to something you said at the outset. I asked you, how would you measure mitochondrial function? And you said, I'd put a needle in somebody and pull out tissue. But that's important because there are lots of people out there that are hawking tests, that are claiming they have tests. They have blood tests, they have breath tests, they have all sorts of tests to measure mitochondrial function. As one of the world's experts on this topic, are you aware of any blood test, breath test, any sort of test that a person can do to measure their mitochondrial function? If they see this, what should they be thinking? I have not looked at all these tests. I don't follow these tests. I don't care to. Simply because in a perfect world, I can't think of how I would design it for all the reasons we just talked about. That's the real problem. I mean, look, if I had one, then maybe this struggling scientist, professionally and personally, would come up with one, Peter. But I got nothing other than a cheap drug called metformin and a glucose monitor. It's difficult for me to imagine how that test looks like and whether it reproducibly measures something that has value. I'm assuming what these tests are trying to measure are content. Well, yeah, I assume I'm also not an expert in this whatsoever. I assume they're measuring metabolic intermediates and they're somehow trying to impute based on your originine, arnathine, citrulline levels, alpha-ketoglutarate levels. Oh, based on that, based on the ratios and levels of all these things, we can tell you how your mitochondrial function. Or acylcarnitine. Yeah. Why is that bogus in your mind? Well, because A, it's in steady state. It doesn't really tell you flux, which is how fast the system is running or not running. You could see an increase in something. Is that because you're running so fast and you still have a lot? Or is it something backed up? That's problem one. Yep. That's the whole C-tap inhibitor problem back when we were dealing with that drug. Yeah. So it's just when I myself haven't done a deep dive on something, I generally try not to be overly critical, but I'm just making a conceptual point that if you and I sat together, for an afternoon and said, here now, tell me all the things I could measure and how would I measure it? Could I come up with a test? No. All right. Let's talk about some of the most popular supplements that people promote. Can I just finish just with cancer real quick? We didn't touch cancer because this is another misnomer. So the original hypothesis of cancer, the number one hypothesis of cancer, not number one, but the oldest from the 1920s was by a gentleman, the Warburg effect that many people have heard. So Otto Warburg got a Nobel prize for the discovery of cytochrome C oxidase, which is the main oxygen consuming enzyme of the electron transport chain. He always truly did his PhD on cytochrome oxidase kinetics. So for me, Otto Warburg has a place for the discovery of that enzyme electron transport chain. So Otto Warburg in the 1920s noticed that cancer tissues does make a lot of lactate on a tabletop compared to normal tissues. There's plenty of oxygen. And so if you have oxygen, you shouldn't be making lactate. So he actually made an intelligent guess, which is that. Mitochondria of those tissue of the cancer is dysfunctional. They're electron transport. He called it injury to respiration. His famous line is a prerequisite for developing cancer. Today, we know that many cancers that make a lot of lactate don't do it because electron transport or injury to respiration. In fact, 95, 98% of cancers have a very intact electron transport chain, TCA cycle. And the reason is because they use it to make ATP, but also, to make those anabolic precursor, the metabolites for growth. There are a few outliers that have a TCA cycle mutation or an electron transport chain mutation. Those tumors that arise, they basically take the macromolecules for growth, the metabolites from growth from the blood. They're good scavengers. Yeah. This is an important point to tease out. So the Warburg effect is in effect. Most cancers adhere to it. It's the causality that's incorrect. It's not that the Warburg effect is the result of deficient electron transport. It's that the Warburg effect is there as a result of a cell that needs to reproduce and grow and grow and grow and create building blocks. The first time I read this was in that very famous 2009 science paper with Matthew and Lou and Craig. So very important distinction. But unfortunately, this is sort of where the internet and people who maybe don't fully understand this will turn it into cancer is a mitochondrial disease. And it's all about your mitochondria. And if you just take mitochondrial supplements, you'll never get cancer. Or if you have cancer, just take mitochondrial supplements. You're going to be fine. This is complete and utter nonsense. Okay. So let's turn to some famous mitochondrial supplements. Urolithin. What can you tell us about Urolithin? We're going to use the metformin principles all over again. Oral, first pass, gut. The gut cells do take it up. The second pass, very quickly, liver. I actually didn't know this until recently. Because I went back and read a very nice paper. I think one of your guests previously might have been on that. I think it was on the paper on inflammation in Urolithin. If you look at the supplementary data, how much is in the plasma of Urolithin of those people who took it? Picograms. Undetectable. Because the liver puts glucuronic acid on it. It says Urolithin and conjugated, which then is in the plasma. So you can barely detect Urolithin in the plasma. It's conjugate, Urolithin plus this sugar moiety is higher, like 5 to 10 micromolar. That moiety cannot get into a cell. Urolithin can't. So what breaks the conjugate? So there are enzymes that can break that conjugate. They're usually found around immune cells, sometimes in muscle repair tumors. But this is a bit of a conundrum I don't quite understand. And I'm sure you appreciate where I'm going with this. It's like, well, hang on, how does this work? Rapidly becomes, so either it's having effects on the gut directly, which it might, and we know how important the gut is. The other thing is that when it's made a conjugate, it has to be deconjugated. And that's happening. In my reading of the enzymes that do this tend to be more related to immune cells. Okay, so that's part one. The second thing is like with metformin, what's its target? So with metformin, people debated, is it complex one? Is it not complex one? Is it complex four? Is it something else? The way we went about showing it's complex one is we found a refractory version of metformin that wouldn't bind and to show it was complex one. So with urolithin, they say it's metophagy, that it promotes bad mitochondria, it gets rid of them. I've missed three steps. How is it even getting into a cell? Well, I don't know that. So the only way it could get into a cell is that locally, immune cells, for example, again, I don't know the literature that well on it. Do we know if there's a urolithin transporter that can get unbound or unconjugated urolithin? I don't think the conjugated one can get in. I think the unconjugated for sure gets in. Clearly, somebody could label urolithin and give it to somebody and then look at where it's taken up. Has that experiment been done? I've never seen it. So that's what the metformin experiment was. Someone took a C11. They said, oh my God, it's in the gut. Someone did an FDG PET. Oh my God, it's in the gut. People like me say, okay, let's focus on the gut. Again, I'm just using the metformin, which can be used, the principles of urolithin. Where does it go? What I do know is that they measured it in the plasma. It seems like a lot of it is converted in the liver to this urolithin plus this sugar molybdenum. That was my simple point. If that's the case, then it has to get deconjugated somewhere in the body, maybe in immune cells, because immune cells can supposedly release the enzyme that deconjugates it. And then the urolithin gets into that localized population. So if you could assume it gets into a cell, how likely is it that it can induce mitophagy? Or what's the evidence that it is doing that? People have seen it induce mitophagy or mitochondrial biogenesis, but where is the target? It's been 10 years. Where's the target? I don't think anybody's ever told me a target or published a target. And it's interesting because metformin is free. There's no money to be made in it, but yet the research has been done. Why is it not the case in urolithin? That that's being done? In other words, is the argument that urolithin is a supplement and that it's over-the-counter and therefore it's not worth studying, whereas metformin is a regulated drug and that's why it's worth studying? I mean, I'm trying to understand why there is such a glaring gap in knowledge for over-the-counter supplements. I would argue there isn't. It's just how efficacious they are. Peter, forgive me. I have to go back to a supplement that's widely used, berberine. Oh, yes. Oh, you're going to like this. So berberine people take. Newsflash, berberine doesn't look like metformin. In our studies, when we give mice berberine, it lowers the glucose levels, okay? If we have NDI1, that yeast refractory in the gut, glucose levels go up. So berberine, as far as I can tell, works exactly like metformin. And gee whiz, metformin is probably cheaper than berberine and is regulated. Use metformin if you're going to use berberine. Sorry. Same concentrations you're seeing in berberine as metformin? We are using the concentrations of berberine that were effective in lowering in mice. We just have to. So we use a concentration of metformin that's widely used to lower glucose levels. We use berberine to lower glucose levels, the lowest dose. It is always interesting that people do prefer a supplement over a drug. It's like, I'd rather have something that's unregulated and I cannot verify the quality versus a drug. But my point is, as far as we can tell, and it's in our preprint paper, people can see it, it acts like metformin, even though structurally it's different. My point is, it's probably like metformin. But you don't have the granular detail for berberine in terms of, you don't actually know where it's binding complex one. You just know it is working on complex one based on the experiment. Right. So let's go back to urolithin. You could ask, now, why don't you work on urolithin? You're a mitochondria guy. Here's another new fascinating drug. Well, okay. So we could start to figure out, there's ways that you can figure out how a drug or a metabolite binds to a protein. There are new techniques. They're called like proteome thermal shift assays. So there's ways to do this. I'm waiting for the aha data in humans or even in mice and the data. So the human trial in muscle, I mean, again, the trials are small. They're not gee whiz. The one that I have liked recently, there was a mouse trial with anti-tumor immunity. That was pretty good. They gave it to see if urolithin would make T cells more effective against a tumor. What did that experiment show? It helped. Why do you think it did? They argued through mitophagy and they did a nice experiment. They knocked out the thing that controls mitophagy and then it didn't work as well. So it's as good of a biological study. So that got me thinking a little bit about urolithin. But the other one is they gave it to people and they looked at CD8 T cell, whether they were exhausted and I think it was in the elderly. And you have some amount of exhaustion and you had a little bit less with urolithin. And again, this is a paper where they show, then the plasma is mainly UDP. Sorry, it's urolithin bound to sugar moiety. But again, there's an effect there, a decreased inflammation. If we're going to use metformin as our baseline, it's the one we know the most about, where do you put the promise of urolithin relative to metformin? I don't see it lowering glucose levels. I don't see any data. Well, I guess the anti-tumor data was good. I think with a lot of these supplements, there may be a window. For example, maybe urolithin could improve anti-tumor immunity and you should use it with CAR T cells. People get CAR T cells for a couple of months. Maybe you could do a urolithin trial in that. Why not? Based on that one study. But compared to metformin, I don't see how it's not remarkably lowering glucose effects or having other effects that we just discussed with metformin. Not enough to make me say, "Let's use that." Okay. What about alpha-ketoglutarate? I like that one a lot and I study it myself. Actually, I study a different version, something in the family of alpha-ketoglutarate. The reason I like it is because alpha-ketoglutarate, we do have targets, probably too many, 75. If alpha-ketoglutarate is there, it's going to run your demethylase enzymes working well and it'll potentially keep DNA methylation levels down, your so-called voodoo epigenetic clocks. Is it keeping methylation down or is it reducing methyl groups? No, no, no. The methyl groups put it on, the DNA. The enzymes that get rid of it, it keeps those enzymes from working well. Here's the only issue. How much do you need for alpha-ketoglutarate? Alpha-ketoglutarate in a cell to run those enzymes maximally, 100 micromolar. You have a lot of alpha-ketoglutarate around. Is it ever rate-limited? Is it ever rate-limiting? I don't know that. As we age, it does go down, but does it go down enough? What's the experiment? What's been done? People are now giving alpha-ketoglutarate. There's a famous study, I think Brian Kennedy's group did that, where the females had a better outcome than males did, the mice did, and they're doing human trials. Hopefully, they'll do them enough that we'll get parameters. I could imagine alpha-ketoglutarate, again, working for inflammation under certain conditions. One of my favorite studies, and I wrote a perspective on it, it's not my study, it came out of other groups, where they gave alpha-ketoglutarate genetically, they manipulated it as a supplement, and it helped against colitis. It happened against 5-FU, the chemotherapeutic drug. In other words, it maintained gut health. It promoted stem cells to become more secretory compared to absorptive, which help maintain gut health. Could you imagine giving alpha-ketoglutarate in those settings? So instead of thinking of a geroprotective narrative, to me, they're going to be niche. And I think people who are doing them, maybe should think about them. You love this study, I know I do, the rapamycin vaccination one. I love that study. But to do this, you really need to go down an IND pathway as opposed to a supplement pathway. You have to turn this into a drug. You have to have an indication. You have to be able to make a claim. You have to be able to test a meaningful and serious hypothesis. Okay, citrulline. Well, we just said that it can. Potentially with metformin. Okay. Carnitine. Well, carnitine helps get fatty acids into the mitochondria. That's what carnitine does. The question is. Is it meaningful? Is it rate-limiting? Is it rate-limiting? I go back to the rate-limiting. Do you, you and I, I assume you're still a meat-eater? I am. If you don't eat meat, they probably get sufficient amount of carnitine to have your fatty acids working. All right. The big one. CoQ10. I think statins, it makes sense sometimes because it can hit the CoQ pathway upstream. So you can imagine certain statins, maybe they get in the muscle high enough or lowering CoQ levels. Does it get to the point where CoQ again becomes rate-limiting? Anecdotally, I mean, you know this better than I do, Peter, people say that the CoQ helps them. I feel like the trials have not been successful. Not shown that, yeah. Again, there's a bioavailability problem. But for what else would you use it for? For normal health? No, you have enough CoQ. Okay. Now we've already talked a little bit about NAD. So anything you want to say about the NAD precursors, NR and NMN? To the listeners, there was a nice article written in the New York Times recently about NAD, does it work? They got a lot of experts. I liked that article a lot. The experts were very good about making their disclosures. They don't have a company, they don't have a company, so that was important. If you read the article, even those experts say, does NAD again decline in normal aging to levels that become rate-limiting? And the answer seems largely no. Could the NAD precursors be used in a special setting? Certain disease. Certain disease. So there's a nice paper that came that liver regeneration can be boosted yesterday by giving NAD supplements. From a reputable group. Sorry, what can be boosted? Liver regeneration. And the mechanisms and what they talked about kind of made sense to me, and it's a nicely done study from a very reputable person at University of Pennsylvania, Joe Bauer. So I like that study. So I can totally imagine. That liver regeneration after liver surgery or after transplant surgery. I mean, it's pretty extreme cases. Pretty extreme, right? Same with, could it work for anti-tumor immunity? Could it work under special conditions, et cetera, et cetera? Absolutely. I'm open to that, but not for geroprotective. I just don't see how. It's based on mitochondrial dysfunction causes the mitochondria not to regenerate NAD, because that's what mitochondria do. Let's give NAD supplements. Yeah, which again, we should point out was unsuccessful in the ITP. Okay, SS31. Now this is actually pharmaceutical grade. This is treating, what's it called? Barth syndrome. Barth syndrome. So this is because there is a mutation in a gene that makes cardiolipin. Cardiolipin is found in mitochondria. Again, it is necessary for cytochrome C oxidase. That Otto Warburg did his research on. Now did his PhD on. And cardiolipin levels dictate the efficiency of that enzyme to work. It uses the oxygen, makes ATP, et cetera. These people have low amounts. And the FDA approved this SS31 as a way to stabilize the little cardiolipin there to boost the efficiency of that enzyme. Some people argue that this SS31 interacts with a lot of proteins. And overall, it's like a glue to the electron transport chain. Here's another one, by the way. I would say we don't know the mechanism at all. The drug is delivered intramuscularly? I don't know how it's delivered. There is not an exact target of that drug or even a good putative hypothesis other than it's cardiolipin. It's a drug that's shown a very, very weak effect in a very, very extreme and rare genetic disease. But it is being touted as a mitochondrial boosting drug that should be taken by everybody. What is the case for that? Again, is your mitochondria rate limiting right now? No. Well, or is cardiolipin rate limiting? Cardiolipin rate limiting. Yeah, because the trial was done in cardiolipin depleted conditions. And I would argue no. Again, the drug could be repurposed in certain mitochondrial mutation patients, which might have some problems. And I'm sure they're going to test it now in those settings. And I hope it works because there, there is a deficiency. But for you and I and for most people, I just don't see that. How about methylene blue, which again has a very clear clinical indication. Beyond the clinical indication, where do you see it? Is it something we should be just generally taking for mitochondrial health? I'm glad you asked methylene blue. We're going to go back to my old friend cytochromoxidase again. Isn't it amazing how all these supplements somehow interact with the things we've been thinking about for years? So what it does is complex one has NADH. It goes to three and four. One and three can generate a superoxide in H2O2. Four cannot. It takes electrons from complex one, methylene blue, from an EDH, and it passes it on to complex IV, which gives it to oxygen. You bypass one and three. Sorry, that's two. Goes from one. So usually you go from one and three. Oh, I thought it was one, two, four. So one and two both go into three of the electron transfer chain. Three goes to four. I'm saying it takes electrons from one and gives it to four. That's what methylene blue does. Now, one and three cannot generate as many electrons for H2O2. So you can imagine diseases where H2O2 signaling is a problem. Maybe methylene blue is a way to decrease those electrons from generating. But again, that's a hypothesis that I have, that that's how, if it could work, it would work. But how much does it get in? And as you know, it can inhibit monamine oxidases, which detoxify dopamine and serotonin. And people on the internet, they don't know that. People on the internet, they don't know that. Hyperbaric oxygen. I get asked about this all the time. It's amazing how many times a week I get asked by somebody if they should buy a hyperbaric oxygen chamber. No, please don't. People are both into high oxygen and low oxygen therapy. This one is for sure bad. Outside of wound healing. Yes, yes. I've worked a lot on both of them. In fact, I got my whole career started on working on low oxygen. And then we moved to high oxygen. What I did was I worked on the hyperbaric oxygen chamber. And I was like, "I'm going to do this for a short amount of time, 60 minutes." If you take people in the ICU and you keep them on high oxygen, I work in an ICU department. I'm not a physician, but I talk to them. They are dying to get those people off high oxygen. Because the longer you keep somebody on high oxygen, and we've done mice experiments on high oxygen, it causes senescence of your lung epithelial cells. It causes cell death. There's been absolutely no benefit to the lung being exposed to that level of oxygen. Now, is 60 minutes going to cause ulcerative colitis? Probably not. But if you're doing it all the time, I don't think it's going to cause cell death, but it might cause cell senescence. And that's my one worry about it. I've worked with high oxygen, mainly in cell culture, mainly in animals. It's nothing good. Do you realize why all of this attention exists? Why are people so obsessed with hyperbaric oxygen? I think it comes back to that Israeli study from a few years ago that looked at telomere length in this. And so, unfortunately, if you were to incorrectly believe that telomere length has anything to do with longevity, you would look at that study and say, but look, these people, they sat in hyperbaric oxygen chambers. Their telomeres got longer. Clearly, that has an anti-aging benefit. Many holes there. Starting with the telomere length hypothesis. Yeah, yeah, yeah. Exactly. These are the kind of holes you can drive 18-wheel trucks through. Yeah. Aside from that study, is there anything else that is generating this belief? Well, I think the other one is more oxygen, better for the mitochondria. Maybe. Okay. Let's talk about the other end of that spectrum. Low oxygen. Low oxygen therapy seems pretty good for athletes. Yeah. So, what's nice about low oxygen is that low oxygen, so high oxygen, there's no receptors for high oxygen. Okay, high oxygen, largely, if it's very high, we've shown this, causes oxidative stress at damaging levels. So, we can engineer a mouse and overexpress one of these antioxidant proteins, and the mouse dies, and now the mouse lives longer. So, we have a pathway, but there's not a direct way hyperoxy is causing that. I think it's just causing so much oxygen that you just make a lot of free radicals or destabilizing the respiratory chain. The low oxygen has a very nice system, which is called the HIF prolyl hydroxylase VHL. Greg Semenza, Peter Ratcliffe, Bill Kalin got that 2019 Nobel Prize. Bill Kalin got a Nobel Prize on this. So, when we're hypoxic, this pathway gets activated. One of the consequences is EPO, erythropoietin, which increases your hematocrit. The other thing is the low oxygen increases your ventilation, right? The pulmonary system vasoconstricts. Those are independent of HIF. Years ago, we showed likely the sensor for those is mitochondrial. There's probably many other things hypoxia does. Is there any reason for a normal person? Well, people argue that about hyperoxia as well, right? More oxygen and more free radicals. So, again, maybe in those sort of things, but just to take it for kicks because you're going to live longer, I don't think so. All right. Let's bring it back to cytochrome again. Red light therapy. Apparently, it hits cytochrome C oxidase, my enzyme. It's weird. So, people say that we always have a little bit of nitric oxide around in our bodies and NO can bind to cytochrome oxidase. And red light therapy would pop it off and make it more efficient. I actually don't know how red light therapy is having its effects in vivo. By the way, the way we showed metformin and complex I inhibition with NDI-1, there is an ancient enzyme, not from yeast, but from C-squirt. If you inhibit complex I, you can override it with this alternative oxidase. So, I have a way to test that. Again, will I test red light theory? Well, unless it's having these clinical trials that show something amazing. We have a good way to test that. I mean, the one thing where clinical trials have definitely shown efficacy for red light is in skin rejuvenation. I feel like I used to know how this worked. Is that working through collagen synthesis? Yeah, but again, years ago, we showed that a little bit of H2O2 in skin cells, in epithelial cells, promoted their differentiation. And people argue that red light therapy could increase a little bit of H2O2, and I wonder if it's the mechanism. We found years ago. So, I wouldn't mind studying it. There's another interesting benefit that you see in some of the trials in red light therapy, which is if you get a significant enough portion of your body covered in red light, you see glucose uptake enhanced. It's actually pretty interesting. I didn't even know that. There was one study that looked at oral glucose tolerance tests, and the AUC, the area under the curve of glucose, went down when a person had X amount of time of their back being hit with red light. Now, I remember when I read this, it was actually a. It was a pretty significant reduction in AUC, but then I did sort of back-of-the-envelope math to see how it compared to exercising. And, of course, it wasn't as much glucose reduction as you would get from an equal amount of time of modest exercise, but it was a lot relative to just laying there, given the fact that you compare it to the placebo. I don't recall thinking through the mechanism. Wait, but doesn't that smell like maybe in the back of the skin, maybe it inhibited cytochrome oxidase, which would then force glucose uptake? Kind of like the gut metformin? Yeah, yeah, I guess that's it. Maybe as simple as that. I remember wondering, and maybe they did, I don't know if they measured lactate, but you would expect to see lactate go up if it was forcing more glycolysis. Yeah, yeah. But the minute you make a lactate in your blood, your heart loves to take up lactate. Lots of tissues love to take up lactate, so. You'd have to make enough to overwhelm the other cells in your body. But maybe, so there's something there. Or again, we can engineer mice where we can make a cytochrome. Cytochrome oxidase homolog that is not red light responsive, and test formally whether red light therapy goes through modulating cytochrome oxidase. I mean, I think this is my big lesson with all of these. You know, find the target. I love your framework. Refractory the target. Where does it go? I love the framework. And then let's look at the human data and how it's efficacious. And all in all, when we just went through these things, to me, metformin, I'm not saying people go run out and use it. It's still better than all of these. It's approved. Lots of people use it. Maybe low-dose anti-inflammatory, maybe cancer, very weak, definitely lower glucose. Take your citrulline and B12. Yeah, I have a feeling I'm going to be getting a lot of questions about this from patients who are going to be wondering, and I mean insulin-sensitive patients. We have lots of patients that do take metformin, but I have to be honest with you, Nav, I'm really on the fence. I just don't know, man. Me too. My family members ask it. The inflammation part, people like the best, I think. I think, but again, it has been the least studied. Yeah. Huh. Maybe that's an interesting case. I take those patients that have persistently elevated CRPs that we otherwise can't come up with any reason for, and maybe we do a metformin trial in those patients and see if we can knock down some inflammation. And measure their clonal hematopoiesis as well. I was just about to say, the chip is also a super interesting thing that I was unaware of. Anyway, Nav, this has been absolutely fascinating. Can I make one other point? Oh, please. Just then, and this is a bit self-serving, I have no conflict of interest, as I said. As we have gone through all these journey about what mitochondria do, and especially all the supplements and all the big drugs, as they all end up doing something, GLP-1, we didn't talk about SGL-2, metformin, all the supplements. supplements, they have something to do with metabolism, something to do with mitochondria. Forty years ago, we started to put money in the Human Genome Project, which I think has been a complete, spectacular success. We know the genome, all the sequencing technologies that came out. We've really gotten the granularity of human genetics more and more. UK Biobank, all of this has come of age. We have never had a moonshot for metabolism, whether it's the government, whether it's a foundation, whether it's philanthropy. To be clear, places like Michael J. Fox Foundation for Parkinson's, and I have a grant from them, and we think Parkinson's is a complex one, disease, and we're trying gene therapy with this NDI-1, and they've given us some money, so I'm very thankful to them. We get some money from the government over the years to do all our work, but it's not at scale, nothing like the Human Genome Project. So my thing is, I know academia, there's some issues, but right now, we should be doubling our efforts in science, especially in metabolism, which has been underfunded for 40 years. I mean, you make a great point. Why do you think that is, Nav? Well, because. Is it simply that it got dwarfed by the genomic revolution? It got dwarfed by the genomic revolution. And you remember, when you were a student, they said, now that we know our genome, we're going to know everything about the human disease 30 years from now. This will not exist. Gene therapy, well, it works great for monogenic diseases and some other diseases, but everything else is idiopathic, unknown ideology. All the toxins. Polygenic, yeah. Yeah, and also the toxins that we're exposed to more and more, like the Parkinson's one, they all hit mitochondria. Yeah, but there hasn't been a large-scale. And people like me were early adopters to metabolism. After the golden generation of metabolism, people have passed away, the Krebs of the world. And so in my world, there hasn't been that many. In the next generation, there's a lot more, but I'm afraid they will probably walk away because there won't be enough money for metabolism because it's dwarfed by the genomic revolution. So I really would like people to make a push for the moonshot of metabolism. But Nav, do you think. I don't think it needs to be philanthropy or government. Do you not think this could be biotech-driven? The best case scenario would be all three. That's what the genomics people did. There's biotech and genomics for sequencing machines that people buy. There's biotech for the drugs, but the basic science comes from the government, and then you have the philanthropy filling in all the holes. I'm just saying, yes, there is parts of it, but it isn't to scale. And I know people are down on academia. I would argue we should double-triple our money. There's biotech for biomedical research. So the last 10 years that you talk about, which I completely agree, is what we want to save. And if we don't have a healthy population last 10 years, we're going to bankrupt the nation because of healthcare costs. You know it and I know it, as people live. At the same time, I'm on record of saying this, and probably you'll get some flack for this, you have the right, Peter, you do, and the taxpayers, and say, "You know what? Are you being as efficient, or are you being as innovative as you should be for the 21st century in academics, current model?" And I don't think that's the case. I think we should be more efficient. I don't think we are. I think it's time that academia change how its business model runs, but at the same time, give us three times as much money in return, okay? So I'm not saying just give us money and we'll keep on doing what we did. We need to change. We need a new model, a new system. I'm very open about it. I will encourage, I know you do notes, I hope you put this, the grand people in science 10 years ago, people who ran Princeton, NIH director, Nobel Prize, there's four of them, who wrote something called "Rescuing the Biomedical Research Enterprise." "Rescuing." They wrote like a white paper in the Proceedings of the National Academy of Sciences, because they're National Academy members, and they outlined what they thought were the problems and solutions. I am not saying we all have to agree on their solutions or even the problems, but it's a pretty good start, and that was 12 years ago. And what came of it? Nothing. Zero. We did the opposite, in my opinion. What were some of the things that they pointed out? No, some of the things about- Like risk-taking? Risk-taking, maybe different style labs, how the costs that the universities impinge on the government. So, in other words, having more skin in the game, so it's just not a revolving business model. They had a lot of good ideas in there, and I'm not the right person who's thought about all of this stuff. What I will say, the biggest challenge is that, like a lot of things in the US, it's become kind of an imperial power at the top, as opposed to decentralized labs and decentralized divisions of biochemistry or medicine. At Google, you have 10 separate divisions that answers to the top, but they're all kind of independent and decentralized. We're way too centralized at every level. And you're saying that not just at the NIH level, but at the university level? Absolutely. At the biomedical research level, way, way, way, way too centralized. There's cancer centers. Everything goes through the dean's office or the president's office. You want a decentralized. You know this better than I do. Decentralized- They don't run like startups. Yeah. So, sorry for the- No, no. I think- I think it's a really important thing. I think that's a super, super interesting point. And we have to keep on. Someone wants to support a moonshot of metabolism. Give me a call. Not just for me, but for the field I'm talking about, okay? All righty. Thanks, man. Great. Thank you. Thank you for listening to this week's episode of The Drive. Head over to peteratiamd.com/shownotes if you want to dig deeper into this episode. You can also find me on YouTube, Instagram, and Twitter, all with the handle peteratiamd. You can also leave us a review on Apple Podcasts or whatever podcast player you use. This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing, or other professional healthcare services, including the giving of medical advice. No doctor-patient relationship is formed. The use of this information and the materials linked to this podcast is at the user's own risk. The content on this podcast is not intended to be a substitute for professional medical advice. Do not use this information in any way, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice from any medical condition they have, and they should seek the assistance of their healthcare professionals for any such conditions. Finally, I take all conflicts of interest very seriously. For all of my disclosures and the companies I invest in or advise, please visit peteratiamd.com/about, where I keep an up-to-date and active list of all disclosures. you

Podcast Summary

Key Points:

  1. Mitochondria do more than produce ATP; they generate signaling molecules like H₂O₂ and metabolites that regulate immune function and epigenetics.
  2. Reactive oxygen species (ROS), such as H₂O₂, are not merely damaging but serve as essential signals for cellular communication, including immune cell activation.
  3. Mitochondrial DNA or RNA release acts as a danger signal, triggering immune responses, and chronic low-level leakage may contribute to age-related inflammation.
  4. Mitochondrial dysfunction is not simply about ATP loss; it may stem from nuanced disruptions in signaling, metabolite levels, or cellular communication.
  5. Antioxidant supplements have failed in clinical trials because the body already maintains sufficient antioxidant capacity, and excessive supplementation may interfere with vital signaling.
  6. Metformin’s benefits may extend beyond glucose control, influencing mitochondrial function through gut-centric and tissue-level mechanisms, though its geroprotective effects remain debated.
  7. Mitochondrial health can be assessed via VO₂ max and lactate threshold testing, which reflect aerobic efficiency and mitochondrial capacity in real-world activity.
  8. Aging is not necessarily driven by mitochondrial dysfunction; genetic and experimental evidence suggests it may be a sufficient but not necessary factor in aging.

Summary:

Mitochondria are far more complex than the "powerhouse of the cell" label implies. Nav Chandell emphasizes that their primary functions extend beyond ATP production to include signaling through reactive oxygen species (H₂O₂), regulation of immune responses via mitochondrial DNA/RNA release, and control of epigenetic processes through metabolites like alpha-ketoglutarate. These signaling roles are crucial for cellular adaptation, immune function, and gene regulation.

Contrary to popular belief, H₂O₂ is not inherently toxic but serves as a key regulator of cellular activity; excessive antioxidant supplementation fails because healthy individuals already maintain sufficient endogenous defenses. The idea of "mitochondrial dysfunction" as a core driver of aging is challenged by evidence showing that mitochondrial mutations—whether in nuclear or mitochondrial DNA—do not rapidly induce aging phenotypes in animals, suggesting it is not a necessary component of aging. Instead, subtle disruptions in signaling and metabolite levels may play a more significant role.

Metformin, a widely used drug, shows complex effects on mitochondrial biology, with evidence for both benefits and limitations, though its anti-aging potential remains inconclusive due to inconsistent clinical trial results. Practical assessment of mitochondrial health can be achieved through exercise-based tests like VO₂ max and lactate threshold, which reflect aerobic efficiency. Ultimately, the conversation shifts from simplistic views of mitochondrial failure to a nuanced understanding of metabolic signaling, cellular communication, and individual variability in aging.

FAQs

Mitochondria perform multiple critical functions: they produce ATP, generate metabolic building blocks like lipids and nucleotides, and act as signaling hubs by producing reactive oxygen species (H2O2) and metabolites such as alpha-ketoglutarate that regulate epigenetics and immune function.

Mitochondrial dysfunction is frequently oversimplified as a failure to produce ATP. In reality, it's more nuanced—problems often arise from miscommunication, such as altered signaling via H2O2 or metabolites, rather than a simple energy deficit.

H2O2 is a key signaling molecule that regulates immune cell activation and differentiation. It helps T-cells form memory cells and triggers type I interferon responses when mitochondria release it in response to pathogens or stress.

Alpha-ketoglutarate regulates epigenetic processes such as DNA and histone demethylation. Its decline with age may contribute to altered gene expression and aging-related dysfunction, especially in tissues like the brain and skin.

Evidence suggests that high-dose antioxidant supplements do not provide health benefits and may interfere with essential signaling. Most people have sufficient endogenous antioxidant capacity, and excessive supplementation can disrupt normal cellular functions.

Mitochondrial DNA or RNA release can trigger immune responses via sensors like cGAS-STING, leading to low-grade inflammation. This is a proposed mechanism for age-related inflammation, though how leakage occurs remains unclear.

Chat with AI

Loading...

Pro features

Go deeper with this episode

Unlock creator-grade tools that turn any transcript into show notes and subtitle files.